Process for preparing new derivatives of 4-/2-hydroxyethyl/-2-oxetanes

A process for the preparation of compounds of formula Г in which Q is hydrogen or a group (Q '), R 3¹ and R² denote C1-C17-alkyl, which optionally contains up to 8 double or triple bonds and which is optionally interrupted by oxygen or sulfur; furthermore denote an optionally substituted phenyl, benzyl or -SaN4-X-CeH5 group, R³R 5 represents hydrogen, C 1 -C 3 -alkyl or C 1 -C 3 -alkanoyl;⁴ represents hydrogen or C1-C8-alk and R5⁵ is hydrogen, an optionally substituted phenyl or phenylalkyl group, and salts thereof of formula I 'in which Q is Q' with acids by cleaving the ether of formula IV, the alcohol of formula I obtained

I-V is optionally esterified with a compound of formula ΙΓ and the oxetanone formed is cleaved, unsaturated residues R¹ and R² are optionally catalytically hydrogenated or otherwise varied within the meaning of the meaning and optionally converted to their salts. The compounds produced inhibit pancreatic lipase and can be used as medicaments in the treatment or prevention of obesity, hypertemia, atherosclerosis and arteriosclerosis.

<img file="CS262425B2_D0001.tif" />

<img file="CS262425B2_D0002.tif" />

d) (&amp;, ')

<img file="CS262425B2_D0003.tif" />

(IV)

OH _d2. R-CH-CH₂

<img file="CS262425B2_D0004.tif" />

W 'R⁵ \ I

N - CH - (CH₂)_n—COOR

OF

R⁴

282425

The present invention relates to a process for the preparation of novel 4- (2-hydroxyethyl) -2-oxethanone derivatives. The compounds produced have valuable pharmacological properties and can be used as active ingredients of drugs.

It is an object of the present invention to provide novel 4- (2-hydroxyethyl) -2-oxethanone derivatives of the general formula Г

<img file="CS262425B2_D0005.tif" />

<img file="CS262425B2_D0006.tif" />

in which

Q is hydrogen or Q '

R³ R⁵ II

N — CH— (СНг) ,, - C—

<img file="CS262425B2_D0007.tif" />

(Q ')

R¹ and R² means an alkyl group having 1 to 17 carbon atoms optionally containing up to 8 double or triple bonds and optionally interrupted by an oxygen or sulfur atom present in a position other than the α-position to the unsaturated carbon atom, or optionally up to three (C 1 -C 6) alkyl, (C 1 -C 6) alkoxy, (C 1 -C 6) alkylthio groups substituted with a phenyl, benzyl or -SaN 4, -X-CeH 5 group, wherein:

X is oxygen, sulfur or (CH2)_Pwhere p is 0 to 3,

R³ represents a hydrogen atom, a (C1-C3) alkyl group or a (C1-C3) alkanoyl group,

R⁴ represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms

R⁵ represents a hydrogen atom, an Ar group or an Ar (C1-C3) alkyl group or an optionally interrupted Y substituent and optionally a Z (C1-C7) alkyl group substituted by Z, or

R⁴ together with R⁵ form a 4- to 6-membered saturated ring,

Y represents an oxygen atom, a sulfur atom or a group:

N (R⁶),

C (O) N⁶) or N (R °) C (O)

Z stands for:

- (0 or S) —R⁷, -N (R⁷, R⁸—C (O) N (R⁷, R⁸) or —N (R⁷JC (O) R⁸, n is 0 or 1, and when n is 1, suibstituent R^withmeans a hydrogen atom,

Ar represents a phenyl group, which is optionally substituted with up to three R groups⁹ or OR⁹, and

R⁶ to R⁹ R &amp; lt; 3 &amp; gt; are hydrogen or C1-C3 alkyl, wherein when Q is hydrogen, R &amp; lt; 3 &amp; gt;¹ R is n-hexyl;² is an undecyl group or a 2Z, 5Z-undecadienyl group, then at least one of the asymmetric carbon atoms present in the oxetanone ring and in the Z-position to the oxetanone ring has the R-configuration and if Q is Q ', R³ represents a formyl group and R is⁵ represents an isobutyl group or R³ represents an acetyl group and R is⁵is kanbamoyimethyl and R is simultaneously² represents an undecyl group or a 2,5-undecadienyl group and R is¹represents n-hexyl, then R⁴ has a meaning other than hydrogen as well as salts of compounds of formula I 'in which Q is Q' with acids, characterized in that

a) cleaves the ether of formula IV

0-L n I

<img file="CS262425B2_D0008.tif" />

in which

R¹ and R² have the above meanings and groupings, whereupon

L is an ether protecting group

b) the obtained alcohol of the formula I-V

<img file="CS262425B2_D0009.tif" />

in which

R¹ and R² are as defined above, optionally esterifying with a compound of formula II '

W 'R⁵ \ I

N — CH— (CH2)_n—COOQ

OF

R⁴ (II ')

<img file="CS262425B2_D0010.tif" />

in which

R¹, R², R⁴, R⁵ and n have the above meanings and

W is an amino protecting group, is cleaved, and

c) unsaturated R groups¹ and R² are optionally catalytically hydrogenated,

d) obtained compounds of the general formula Γ in which Q is Q 'and at least one in which

W * is an amino protecting group W or a residue R³, and

Q, R³, R⁴, R⁵ and n are as defined above, and the oxetanone of formula XX formed from R is formed³ and R⁴ represents hydrogen and one of the amino groups Y or Z optionally contained in the substituent R^withis tertiary, optionally alkanoylated to give an alkanoyl group having 1 to 3 carbon atoms, and

e) optionally obtaining compounds of the general formula Γ in which Q represents a group Q ', by reaction with weak acids into their salts and isolated in the form of salts.

Oxethanones of formula (I) - R (R) O;

J 4 -CH- (CH 2 -C (t-AJ) in which

R¹, R², R³, R⁴, R⁵ and n are as defined above, which are within the scope of the compounds of the formula Γ, form salts with weak acids, the preparation of which is also within the scope of the invention. Examples of such acids include:

p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, fumaric acid, ascorbic acid, maleic acid, malic acid, citric acid and phosphoric acid.

The oxetanones of formula I-A contain at least 3 asymmetric carbon atoms and oxetanones of formula I-V

<img file="CS262425B2_D0011.tif" />

<img file="CS262425B2_D0012.tif" />

they may contain one or more as present in the form of optically active enantiomeric carbon atoms. They may therefore be thiomers, as diastereomers or as mixtures, for example as racemic mixtures.

The esterification according to step bj of the process of the invention may be carried out in a solvent, for example an ether such as tetrahydrofuran, in the presence of triphenylphosphine and diethyl ester of azodicarboxylic acid, preferably at a temperature around room temperature.

The corresponding anhydride can be used as a functional derivative of the acid of formula II.

Examples of the amino protecting group W in the compound of formula (ΙΓ) include benzyloxycarbonyl and p-nitrobenzyloxycarbonyl. The cleavage of this amino protecting group W can be carried out by hydrogenation in a solvent, for example an ether such as tetrahydrofuran, in the presence of a hydrogenation catalyst such as palladium on carbon, preferably at room temperature.

The optional hydrogenation according to step c) of the process according to the invention can be carried out under similar conditions to those employed for the cleavage of the amino-protecting group W.

The optional C 1 -C 3 alkanoylation of step (d) of the process of the invention may be carried out in the presence of an acid anhydride, for example a mixed acid anhydride such as formic and acetic anhydride, in a solvent such as an ether such as tetrahydrofuran, preferably at room temperature.

Examples of ether protecting groups L include:

tetrahydro-2H-pyran-2-yl, 1-ethoxyethyl, benzyl and tert-butyldimethylsilyl.

The cleavage of the ether protecting group L can be carried out in a solvent, for example an alcohol such as ethanol, in the presence of pyridinium 4-toluenesulfonate with heating, for example at a temperature of 50 to 65 ° C.

Ethers of formula IV can be prepared by cyclization of acids of formula V

O — OH OH COOH

AND

R²-CH-CH2-CH-CH-R¹ (V) in which

L, R¹ and R² are as defined above, wherein said reaction can be carried out in a solvent such as pyridine under cooling, for example to 0 ° C, in the presence of benzenesulfochloride.

The acids of formula V may be prepared either

a) saponification of the corresponding esters of formula VI

O — OH OH

R²-CH-CH2-CH-CH-R¹ in which

R is C 1 -C 4 alkyl and

L, R¹ and R² are as defined above, or

b) condensation of an acid of formula VII

R¹—CH2 — COOH (VII) wherein

R¹ is as defined above, with an aldehyde of formula VIII

O — L

R²—CH2 —CH2 —CHO (VIII) wherein

L and R² are as defined above.

Examples of alkyl groups R may be methyl, ethyl or tert-butyl. The saponification of the ester of formula (VI) according to variant a) can be carried out by treatment with an alcoholic alkali metal hydroxide solution or an alcoholic alkaline earth metal solution such as methanolic potassium hydroxide solution, by heating to reflux until the reaction mixture is refluxed.

The condensation of an acid of formula VII with an aldehyde of formula VIII according to variant b) can be carried out in a solvent such as tetrahydrofuran in the presence of idiisopropylamine and butyllithl, with cooling, for example to -50 ° C.

The acids of the formula V which occur in the · (5RJ- or (5S) -form) can be converted to the (2S, 3S, 5R) - or (2R, 3R, 5S) -stereoisomers as follows:

The (5R) - or (5S) -acid of formula V is cyclized, for example by heating at 50 to 60 ° C in ethanol, by treatment with toluene-4-sulfonic acid monohydrate to give the corresponding (6R) - or (6S) - of the pyranolone of formula V-A

<img file="CS262425B2_D0013.tif" />

in which

L 'represents a hydrogen atom;

R¹ and R² are as defined above.

This (6R) - or (6S) -pyranolone is then oxidized, for example in acetone by (j) with a jones reagent at a temperature below 25 ° C, to the corresponding pyran-2,4-dione and this is stereospecifically hydrogenated, for example in ethyl acetate in the presence of platinum oxide to the (3S, 4S, 6RJ- or (3R, 4R, 6S) -pyranolone of formula V-A wherein L 'is hydrogen.

This pyranolone is converted to a compound of formula V-A wherein L 'is an ether protecting group such as a t-butyldimethylsilyl group, for example in dimethylformamide, with t-butyldimethylchlorosilane. The obtained cyclic (3S, 4S, 6RJ- or (3R, 4R, 6S) -ether is cleaved, for example by treatment with an aqueous solution of potassium hydroxide in dioxane, and the resulting compound is converted in situ to (2S, 3S, 5R) or (2R, The 3R, 5S) -ether of formula V-V

O — L “O — L * COOR¹⁰

R²—C'H — CH2 — CH — CH — R¹ (V — B] in which

L 'represents a hydrogen atom,

L 'is the same protecting group of the ether group as in the ether of formula V-A,

R¹⁰ represents a benzyl group or a p-initrobenzyl group, and

R¹ and R² are as defined above.

The ether of formula (V-V) is then converted to a diether of the same formula wherein L 'is an ether protecting group such as tetrahydro-2H-pyran-2-yl. After cleavage first of the protecting group of the ether group L ', for example with tetrabutylammonium fluoride trihydrate in tetrahydrofuran, and then of the group R¹⁰by hydrogenation in tetrahydrofuran in the presence of palladium on carbon, gives the desired (2S, 3S, 5R) - optionally (2R, 3R, 5S) -acid of formula V.

Esters of formula VI can be prepared either

a) alkylation of the corresponding esters of formula IX

O-OH

II

R²—CH — Nг — CH-CH2 — COOR (IX) wherein

R, R² and L are as defined above, or

b) reduction of the Z-keto ester of formula X

O — LO COOR

R²—CH — CH2 — С, —CH — R¹ in which

R, R¹, R² and L are as defined above.

Alkylation according to variant a) can be carried out by reacting an ester of formula IX in a solvent such as tetrahydrofuran, by treating a solution of n-butyllithium in a solvent such as n-hexane in the presence of diisopropylamine at about -50 ° C, followed by reaction with a solution. alkyl halide [R¹Hal), for example bromide, in hexamethylphosphoric triamide at a temperature of about 0 to 10 ° C.

The reduction according to variant b) of the ketoester of formula X can be carried out under an atmosphere of an inert gas such as argon in a solvent such as tetrahydrofuran by treatment with a complex metal hydride such as sodium borohydride (NaBH 4) at a temperature below 0 ° C.

Esters of formula IX may be prepared by reductive removal of the sulfoxide group in the sulfoxide of formula XI

OL OH COOR _n oii ¹

R-CH-CH 2 CH-CH-S (XI) wherein

T represents a p-tolyl group, and

L, R and R² are as defined above.

This reaction can be carried out, for example, in a solvent such as tetrahydrofuran by treatment with aluminum amalgam.

The β-keto esters of formula X can be prepared by reacting an aldehyde of formula X.

R²—CHO in which

R² is as defined above, with the β-keto ester of formula XII

COOR

O = C — CH — R¹

СНз (ХП) in which

R and R¹ are as defined above, and etherifying the obtained alcohol of formula XIII

OH O COOR

I II I

R²—CH — CH2 — С, —CH — R¹ (XIII) (X) wherein

R, R¹ and R² are as defined above.

The preparation of the alcohol of the general formula (XIII) or its etherification can be carried out, for example, as described in Examples H or J, section e).

Unsaturated R groups¹ and R²which are contained in the intermediates of formulas XX, III to VI, V - V, X and XIII may optionally be hydrogenated, for example under the conditions of hydrogenolytic cleavage of the group W or R¹⁰already mentioned above.

The sulfoxides of formula XI can be prepared by condensation of the aldehyde of the above formula VIII with an ester of formula XIV 'Ч

S - CM-COOR (Х1У) where

T and R have the meanings given above, for example as described in Example G below.

The aldehydes of formula VIII can be prepared by reduction of esters of formula XV

O — L: I.

R²—CH — CH2 — COOR (XV) wherein * '

R, R² and L are as defined above, for example, dialkyl aluminum hydride containing from 1 to 4 carbon atoms in the alkyl groups, such as diisobutylaluminum hydride, in a solvent such as toluene at a temperature of about -60 to -80 ^qC.

Esters of formula XV may be prepared from aldehydes of formula

R²—CHO in which 'R² is as defined above, through the sulfoxides of formula XVI

OH COOÍ?

л I í Л

PCH-CH-s in which

T and R² are as defined above, and esters of formula XVII

OH

R²-CH-CH 2 -COOR (XVII) wherein

R and R² have the above meaning, for example as described in the following paragraphs Fa), Fd) and Ff); Gb), Gd) and Gf) and Jb), Jd) and JI).

Further, esters of the general formula XV in which R @ 1² is a 3-alkenyl group, prepared by ozonolysis of an ester of formula XVIII

CH2 OL

II I

CH-CH 2 —CH-CH 2 -COOR (XVIII) wherein

R and L are as defined above, and by Wittig reaction with the aldehyde XIX obtained

OO — L

II

CH-CH2-CH-CH2-COOR (XIX) wherein

L and R have the meanings given above, for example as described in Examples K) and L).

For the conversion of aldehydes of formula VIII or aldehydes of formula

R²—CHO in which

R² (R) - # (hydroxydiphenylmethyl) benzyl acetate may be used in place of the sulfinyl ester of formula (XIV), in which case they are obtained instead of the sulfoxides of formulas (XI) or (XVI (R)) -2-hydroxy-1,2,2-triphenylethyl esters corresponding to alkyl esters of formulas IX and XVII, respectively.

Oxethanones of formula XX can be prepared in the same manner as oxethanones of formula Г, for example as described in the following Example 2.15, by esterifying a compound of formula ΙΓ in which W 'is an amino protecting group with an alcohol of formula I-B. In this esterification, the acid of formula kyseliny acid anhydride obtained by reaction with N-ethyl-N '- (3-dimethylaminopropyl) carbo (XVI) diimide hydrochloride or preferably with dicyclohexylcarbodiimide can be used as described for example in Example 10 B1).

The preparation of the intermediates of formulas (IV) to (XIX) is described in more detail in the following paragraphs A. to M.

A. Production of ethers of formula IV:

Aa) 0.57 g of a mixture of diastereomers consisting, inter alia, of (2S, 3S, 5R, 13Z, 16Zj-2-hexyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yljoxy)] 13,16 of docosadienoic acid is dissolved in 10 ml of pyridine and the solution is cooled to 0 DEG C. After the dropwise addition of 0.28 ml of benzenesulfochloride, the reaction mixture is stirred for a longer time at 0 DEG C. The reaction mixture is then poured into 120 ml. 10% aqueous sodium chloride solution and extracted three times with 30 ml diethyl ether. The combined extracts were dried, filtered and the filtrate was evaporated. After chromatography on silica gel, a mixture of diastereomers of 3-hexyl-4 - ((10Z, 13Z) -2 - [(tetrahydro-2H-pyran-2-yl) oxy] -10,13-nonadecadienyl] -2-oxetanone is obtained as colorless oils.

IC spectrum: 1,815 cm -1¹.

The following compounds are obtained in an analogous manner:

Ab)

3-ethyl-1-4-1 (10Z, 13Z) -2 - [(tetrahydro-2H-pyran-2-yl) oxy] -10,13-nonadecadienyl] -2-oxethanone,

IR: 1820 cm¹(13Z, 16Z) -2-ethyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] -13,16-docosadienoic acid starting material;

Ac) (3S, 4S) -3-ethyl-4 - ((R, Z) -2 - [(tetrahydro-2H-pyran-2-yl) oxy] -10-nonadecenyl-2-oxetanone from (2S, 3S, 5R, Z) -2-ethyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] -13-docosenoic acid starting material;

(Ad) (3-Benzyl-4 - {(10Z, 13Z) -2- [tetrahydro-2H-pyran-2-yl) oxy) -10,13-nonadecadienyl] -2-oxethanone,

IC spectrum: 1818 cm¹ from (13Z, 16Z) -2-benzyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] -13,16-docosadienoic acid starting material;

Ae] (3S, 4S) -3-ethyl-4- (S) -phenoxy-8 - ((tetrahydro-2H-pyran-2-yl) oxy] phenethyl) -2-oxethanone from (2S, 3S, 5S) -2-ethyl-3-hydroxy-5- (p-phenoxyethyl) -5- [tetrahydro-2H-pyran-2-yl) oxy] valeric acid starting material;

Af) (3S, 4S) -3-hexyl-4 - ((S) -phenoxy-β - [(tetrahydro-2H-pyran-2-yl) oxy] phenylethyl-2-oxethanone,

IC spectrum: 1815 cm¹ starting from (2S, 3S, 5S) -2-hexyl-3-hydroxy-5- (p-phenoxyphenyl) -5 - ((tetrahydro-2H-pyran-2-yl) oxy) valeric acid;

Ag)

3-Hexyl-4-12 - [(tetrahydro-2H-pyran-2-yl) oxy] tridecyl] -2-oxethanone from 2-hexyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl)] oxy] hexadecanoic acid starting material;

Ah)

3-Hexyl-4 - ((R) -2 - [(tetrahydro-2H-pyran-2-yl) oxy] tridecyl] -2-oxethanone from 2-hexyl-3-hydroxy- (R) -5 - [( tetrahydro-2H-pyran-2-yl) oxy] hexadecanoic acid starting material;

Ai)

3-ethyl-4- [2 - ['(tetrahydro-2H-pyran-2-yl) oxy] tridecyl] -2-oxethanone from 2-ethyl-3-hydroxy-5 - [(itetrahydro-2H- pyran-2-yl) oxy] hexadecanoic acid;

Aj)

3-methyl-4 - ((R) -2 - ((tetrahydro-2H-pyran-2-yl) oxytridecyl) -2-oxethanone from 2-methyl-3-hydroxy (R) -5 - ((tetrahydro -2H-pyran-2-yl) oxy] hexadecanoic acid starting material;

If)

3-Allyl-4- [2 - [(tetrahydro-2H-pyran-2-yl) oxy] tridecyl] -2-oxethanone from 2-allyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2- yl) oxy] hexadecanoic acid starting material;

AI)

3-Hexyl-4 - [(R) - ((tetrahydro-2H-pyran-2-yl) oxy] propyl) -2-oxethanone from 2-hexyl-3-hydroxy (R) -5 - [(tetrahydro- 2H-pyran-2-yl) oxy] hexanoic acid Starting materials;

Am)

3-Hexadecyl-4- (2 - [(tetrahydro-2H-pyran-2-yl) oxy] propyl] -2-oxethanone from 2-hexadecyl-3-hydroxy (R) -5 - [(tetrahydro-2H- pyran-2-yl) oxy] hexanoic acid starting material;

An)

3-Hexyl-4 - ((2 - [(tetrahydro-2H-pyran-2-yl) oxy] -5-hexenyl] -2-oxethanone from 2-hexyl-3-hydroxy-5 - [(tetrahydro-2H- pyran-2-yljoxy] nonenoic acid starting material;

Ao)

3-Decyl-4 - ((R) -2 - [(tetrahydro-2H-pyran-2-yl) oxy] -5-hexenyl] -2-oxethanone from 2-decyl-3-hydroxy (R) -5- [(tetrahydro-2H-pyran-2-yl) oxy] nonenoic acid starting material;

Ap]

3-Hexyl-4- ((R) -2 - [(tetrahydro-2H-pyran-2-yl) oxy] -5-triidecenyl-2-oxetanone-yloxy] -5-tridecenyl] -2-oxetanone 2-hexyl-3-hydroxy (R) -5 - [(tetrahydro-2H-pyran-2-yl) oxy] hexadecenoic acid starting material;

Aq)

3-Hexyl-4 - ((R-2 - [(tetrahydro-2H-pyran-2-yl) oxy] -5-hexenyl) -2-oxethanone from 2-hexyl-3-hydroxy- (R) -5- [(tetrahydro-2H-pyran-2-yl) oxy] nonenoic acid starting material.

B. Production of acids of formula V:

Ba] 1.0 g of a crude mixture of (12Z, 16Z) -2-hexyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] -13,16-docosadienoic acid tert-butyl ester tert-butyl ester The reaction mixture was cooled and poured into 60 ml of ice-water, the pH was adjusted to 1 by dropwise addition of 1M aqueous hydrochloric acid solution, followed by thorough extraction. ether.

The combined ether phases were dried, filtered and the filtrate was evaporated. The oil obtained is chromatographed on silica gel to give a mixture of diastereomers (13Z, 16Z-2-hexyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] -13,16-docosadienoic acid in m.p. oil.

IR spectrum:

350, 1 709, 1 132, 1 078 and 1 023 cm -1¹.

The following compounds are obtained in an analogous manner:

Bb) (13Z, 16Z) -2-ethyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl-yloxy) -13,16-docosadioic acid from tert-butyl ester (13Z, 16Zj-2-ethyl) 3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] -13,16-dodecadiadienoic acid as a starting material;

Bq) (2S, 3S, 5R, Z) -2-ethyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] -13-docosenoic acid from tert-butyl ester (2S, 3S, 5R, Z-2-ethyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-8-yl) oxy] -13-docosenoic acid starting material;

Bd) (13Z, 16Z) -2-ibenzyl-3-hydroxy-5 - [(tetrahydro-2H-ipyran-2-yl-yloxy) -13,16-docosadienoic acid, mass spectrum: 458 (M)⁺-dihydropyran);

IC spectrum: 3,008, 1,709, 1,160, 1,134, 1,115 cm^-1 from (13Z, 16Z) -2-benzyl-3-hydroxy - [(tetrahydro-2H-pyran-2-yl) oxy] 13,16-docosadlenic acid tert-butyl ester;

Be (2S, 3S, 5S) -2-ethyl-3-hydroxy-5- (p-phenoxyphenyl) -5- (:( tetrahydro-2H-pyran-2-yl) oxy] valeric acid from tert-butyl ester (2S) 3S, 5S) -2-ethyl-3-hydroxy-5- (phenoxyphenyl) -5 - [(tetrahydro-2H-pyran-2-yl) oxy] valeric acid starting material;

Bf) (2S, 3S, 5R) -2-Hexyl-3-hydroxy-5- (phenoxyphenyl) -5 - [(tetrhydro-2H-pyran-2-yl) oxy] valeric acid from tert-butyl ester ( 2S, 3S, 5R-2-hexyl-3-hydroxy-5- (phenoxyphenyl) -5 - [(tetrahydro-2H-pyran-2-yl) oxy] valeric acid starting material;

Bhj

2-hexyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] hexadecanoic acid from 2-hexyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yljoxy) methyl ester] hexadecanoic acids as starting materials.

C. Production of acids of general formula V (another variant)

Ca) 2 ml of diisopropylamine in 30 ml of absolute tetrahydrofuran is cooled to -20 ° C. ^CAnd then 9.68 ml of butyllithium (1.6M in hexane) is added dropwise to the solution so that the temperature does not exceed -20 ° C. ⁴C. The reaction mixture was then stirred for 15 minutes and then cooled to -50 ° C. Then, 0.720 ml of 4-pentenoic acid in 10 ml of tetrahydrofuran was added dropwise and the reaction mixture was stirred for a further 10 minutes at -50 degrees Celsius. Then the reaction mixture was stirred at room temperature for 1 hour and then cooled again to -50 ° C. 2 g of rac-3 - [(tetrahydro-2H-pyran-2-yl) oxy] tetradecanol in 10 ml of tetrahydrofuran are now added dropwise and the reaction mixture is stirred for a further 30 minutes at -50 [deg.] C. and then for 72 hours at room temperature.

After hydrolysis with 2N hydrochloric acid, the reaction mixture was evaporated. The residue was extracted with ether. The organic phase was dried over sodium sulfate, filtered and evaporated. The product obtained is chromatographed over a silica gel column. Crude 2-allyl-3-hydroxy-5 - ((tetrahydro-2H-pyran-2-yl) oxy] hexadecanoic acid was obtained.

The following compounds are obtained in an analogous manner:

Cb)

2-ethyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] hexadecanoic acid from rac.-3 - [(tetrahydro-2H-pyran-2-yl) oxy] tetradecanal and butanoic acid as starting materials ; '

Cc)

2-methyl-3-hydroxy (R) -5 - [(tetrahydro-2H-pyran-2-yljoxy) hexadecanoic acid from (R) -3 - [(tetrahydro-2H-pyran-2-yl) oxy] tetradecanal and propionic acid starting materials;

CD)

2-hexyl-3-hydroxy (R) -5 - ((tetrahydro-2H-pyran-2-yljoxy) hexanoic acid from (R) -3 - [(tetrahydro-2H-pyran-2-yl) oxy) butanal and octanoic acid starting materials;

Ce)

2-Hexadecyl-3-hydroxy-5 - [(tetrahydr o-2H-pyran-2-yl) Joxy] hexanoic acid from 3 - [(tetrahydro-2H-pyrain-2-yl) oxy] butanal and octadecanoic acid as starting materials ;

Cf)

2-Hexyl-3-hydroxy- (R) -5 - ((tetrahydro-2H-pyran-2-yl) oxy] -8-nonenoic acid from (R) -3 - [(tetrahydro-2H-pyran-2- yl) oxy] -6-heptenal and octanoic acid starting materials;

Cg)

2-Decyl-3-hydroxy- (R) -5 - [(tetrahydro-2H-pyran-2-yl) -oxy] -8-nonenoic acid from (R) -3 - ((tetrahydro-2H-pyran-2- yljoxy] -6-heptanal and dodecanoic acid starting materials;

Ch)

2-Hexyl-3-hydroxy- (R) -5 - [(tetrahydr o-2H-pyran-2-yl) oxy] -8-pentadecenoic acid from (R) -3 - [(tetrahydro-2H-pyran-2- yl) oxy] -6-tetradecenal and octanoic acid starting materials;

Cl)

2-hexyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] -8-nonenoic acid from 3 - [(tetrahydro-2H-pyran-2-yl Joxy) -6-heptenal and octanoic acid as starting materials.

D. Preparation of esters of formula VI

Da) 3.1 ml of diisopropylamine was cooled to -5 ° C under argon, and 14 ml of an approximately 1.6 M solution of n-butyllithium in hexane was added dropwise. The reaction mixture was then stirred for 10 minutes. After cooling to -50 ° C, the cooling bath was removed and a solution of 5.08 g of a mixture of (13Z, 16Z) -3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] dlastereomer dlastereomers was added dropwise. 13,16-dicosadienoic acid in 5 ml tetrahydrofuran. The temperature of the reaction mixture rose to -20 ° C. The reaction mixture was allowed to warm to 0 ° C at this temperature and stirred for 10 minutes

Then a solution of 2.1 ml of 1-bromohexane in 2.5 ml of hexamethyltriophosphoric acid was added to the reaction mixture, the reaction temperature rising to 9 ° C. The reaction mixture was then allowed to warm to room temperature and stirred at room temperature for a period of time

2.5 hours. The reaction solution was poured onto 200 ml of ice water and saturated with brine. Extraction with ether is then carried out. The combined ether extracts were dried, filtered and evaporated. The residual oil is chromatographed on silica gel. A mixture of diastereomers of (13Z, 16Z1 -2-hexyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] -13,16-docosadienoic acid tert-butyl ester is obtained.

Mass spectrum:

519 (M ⁺ - (СНз) зСО—).

IC spectrum:

503, 1,728, 1,700 -and 1153 cm-¹.

The following compounds are also obtained in an analogous manner:

Db) (13Z, 16Z) -2-ethyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] -13,16-docosadienoic acid tert-butyl ester,

Mass Spectrum: 396 (M &amp; lt; + &amp; gt;)⁺(dihydropyran-isobutylene);

IC spectrum:

510, 1728, 1153, 1137 cm¹;

from (13Z, 16Z) -3-hydroxy-5- tert -butyl ester

[(letrahydro-2H-pyran-2-yl) oxy] -13,16-docosadienoic acid and ethyl iodide as starting materials;

Dc) (13Z, 16Z) -2-Benzyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] -13,16 docosadienoic acid tert-butyl ester,

Mass Spectrum: 525 [M⁺ - (НзС) зСО—];

IR spectrum:

498, 1725, 1 604, 1585, 1496, 1150 cm¹, from tert-butylister (13Z, 16Z) -3-hydroxy-5-

- [(tetrahydro-2H-pyrain-2-yl) oxy] -13,16-docosadienoic acid and benzyl bromide as starting materials;

Dd) tert-butyl ester (2S, 3S, 5R, Z) -2-ethyl-3-hydroxy-5 - [(tetrahydroxy)^ando-2H-pyran-2-yloxy) docosenoic acid,

Mass Spectrum: 465 [M⁺ - (НзС) зСО);

IC spectrum:

499, 1729, 1155, 1137, 1116 cm¹from (3S, 5R, Z) -3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] -13-docosenoic acid tert-butyl ester and ethyl iodide as starting materials;

(2S, 3S, 5R) -2-Ethyl-3-hydroxy-5- (phenoxyphenyl) -5 - [(tetrahydro-1H-pyran-2-yl) oxy] valeric acid tert-butyl ester from tert. [3S, 5R) -3-Hydroxy-5- (phenoxyphenyl) -5 - [(tetrahydro-2H-pyran-2-yl) oxy] valeric acid butyl ester and ethyl iodide starting material;

Df] [2S, 3S, 5R) -2-Hexyl-3-hydroxy-5- (phenoxyphenyl) -5 - ((tetrahydro-2H-pyran-2-yl) oxy] valeric acid tert-butyl ester from tert. (3S, 5R) -3-Hydroxy-5- (p-phenoxyphenyl) -5 - ((tetrahydro-2H-pyran-2-yl) oxy] valeric acid butyl ester and 1-bromohexane starting material;

Dg) 2-Hexyl-3-hydroxy (R) -5-

- [(tetrahydro-2H-pyran-2-yl) oxy] hexadecanoic acid, silica gel thin layer chromatography (using a solvent system of a 1: 1 mixture of hexane and diethyl ether): R = 0.65, from tert. 3-hydroxy (R) -5 - [(tetrahydro-2H-pyran-2-yl) oxy] hexadecanoic acid butyl ester and 1-bromohexane starting material.

E. Production of esters of formula VI (another variant)

7.76 g (0.017 mol) of 2-hexyl-3-oxo-5- methyl ester are dissolved under argon.

- [(tetrahydro-2H-pyran-2-yl) oxy] hexadecanoic acid in 500 ml of tetrahydrofuran, 20 ml of methanol are added to the obtained solution, and the reaction mixture is cooled to -5 ° C. 5.3 g (0.14 mol) of sodium borohydride are then added portionwise with stirring so that the temperature of the reaction mixture does not exceed 0 ° C. After stirring for 3 hours, excess sodium borohydride is filtered off, the reaction mixture is cold hydrolyzed with 2N hydrochloric acid solution and the solvent is evaporated. The residue is extracted with ether and the ether phase is dried and evaporated. 7.71 g of 2-hexyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] hexadecanoic acid methyl ester is obtained.

F. Production of esters of formulas XVII and IX

Fa) 147.6 g of a mixture of tert-butyl ester (11Z, 14Z) -3-hydroxy-2 - [(R) -o-tolylsulfinyl] -1,14-eicosadienoic acid diastereomer is dissolved in 5,500 ml of tetrahydrofuran and po2SO2. 190 g of amalgamated aluminum foil are added over a period of 6 hours, maintaining the temperature of the reaction mixture between 15 and 20 [deg.] C. After completion of the addition, the reaction mixture is stirred until the reaction is complete. tetrahydrofuran and then 2 liters of tetrahydrofuran. The filter cake is taken up with 2 liters of diethyl ether, stirred vigorously and filtered again. This procedure is repeated once more. The combined organic phases were evaporated and the oily residue purified by chromatography on silica gel to give a mixture of enantiomers consisting of 80% (R, 11Z, 14Z) -3-hydroxy-11, -14-eicosadienoic acid tert-butyl ester, mass spectrum : 324 (M⁺-isobutylene);

IC spectrum:

452, 1 715, 1 154 tin-¹.

The following compounds are obtained in an analogous manner:

Fb) (13Z, 16Z) -3-Hydroxy-5 - [(tetrahydro-2H-pyro-2-yl) oxy] -13,16-docosadienoic acid tert-butyl ester,

1C spectrum:

481, 1730, 1153, 1 075, 1 014 cm¹, from (13Z, 16Z) -3-hydroxy-5 [(tetrahydro-2H-pyran-2-yl) oxy] -2 - [(S) -p-tolylsulfinyl] -13,14-docosadienoic acid tert-butyl ester ;

(3S, 5R, Z) -3-Hydroxy-5 - [(tetrahydro-2H-1-pyran-2-yl-yloxy) -13-docosenoic acid tert-butyl ester, Mass Spectrum: 437 [M · - (НзС) ) зСО]

IC spectrum:

484, 1 730, 1 655, 1 153, 1 075,

024 cm '¹, from (3S, 5R, Z-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl-yloxy) -2- (S) -p-tolylsulfinyl] -13-docosenoic acid tert-butyl ester as starting material ;

Fd) (R, Z) -3-Hydroxy-11-eicosenoic acid tert-butyl ester,

IC spectrum:

445, 1,716, 1,154 cm '¹,

5 from (R, Z) -3-hydroxy-2 - [(R 1 -p-tolylsulfinyl) -1,1-eicosenoic acid tert-butyl ester starting material;

(3S, 5S) -3-Hydroxy-5- (p-phenoxy-phenyl) -5 - [(tetrahydro-2H-pyran-2-yl) oxy] valeric acid tert-butyl ester, Mass Spectrum: 357 (M)⁺ - tetrahydropyranyl),

IC spectrum:

446, 1 727, 1 590, 1 505, 1 489, 1 152,

133, 1 118, 1 074, 1 022 cm-1¹, from (3S, 5S) -3-hydroxy-5- (p-enoxyphenyl) -5 - [(tetrahydro-2H-pyran-2-yl) oxy] -2 - [(S) -o-tolylsulfate tert-butyl ester] inyl] valeric acid;

Ff) [(S] - N -hydroxy-p-phenoxybenzyl] acetic acid tert-butyl ester, melting point: 64-65 ° C (from n-hexane), mass spectrum: 314 (M)⁺),

IC spectrum:

440, 1,713, 1,590, 1,506, 1,491, 1,158 cm '¹from tert-butyl (S) - β-hydroxy-β-phenoxy-α - [(R 1 -p-tolylsulfinyl) hydrocinnamic acid starting material;

Fg) 3-Hydroxy- (R) -5 - [(tetrahydro-2H-pyran-2-yl-yloxy) -hexadecanoic acid tert-butyl ester from tert-butyl 3-hydroxy-(R) -5-tetrahydro-2H-pyran-2 -yl] oxy] -2 - [(S) -p-tolylsulfinyl] hexadecanoic acid starting material.

G. Production of sulfoxides of formulas XI and XVI

Ga)

16.5 g of [(S) -p-tolylsulfinyl] acetic acid tert-butyl ester are dissolved in a mixture of 600 ml of ether and 60 ml of tetrahydrofuran and the solution is cooled to -78 ° C. 43 ml of t-butyl magnesium bromide are then added dropwise so that the temperature is still below -70 ° C. After stirring at -78 ° C for 1 hour, 13.4 g of [R) -3 - [(tetrahydro-2H-pyran-2-yl) oxy] tetradecanal in 100 ml of tetrahydrofuran was added dropwise. After 2 hours at -78 ° C, the reaction mixture is hydrolyzed by the addition of 2N hydrochloric acid solution and then the solvent is evaporated. The remaining reaction mixture was extracted with ether and the ether phase was dried and evaporated. After chromatography on silica gel, 14.9 g of 3-hydroxy- (R) -5 - [(tetrahydro-2H-pyran-2-yl) oxy] -2 - [(S) -p-tolylsulfinyl] tert-butyl ester is obtained. ] hexadecanoic acid. Yield: 67%.

Melting point: 97 to 98 ^QC.

The following compounds were prepared in an analogous manner:

Gb) (3R, 11Z, 14Z) -3-Hydroxy-2 - [(R) -p-tolylsulfinyl] -11,14-eicosadienoic acid tert-butyl ester,

IR spectrum:

400, 1727, 1 653, 1 596, 1 494, 1 279,

258, 1 145, 1 085, 1 045 cm-1¹starting from 9,12-octadienal and (R) -p-tolylsulfinylacetic acid tert-butyl ester;

Gc) (13Z, 16Z) -3-Hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] -2 - [(S) -p-tolylsulfinyl] 13,16-docosadienyl acid tert-butyl ester from (11Z, 14Z) -3 - ((tetrahydro-2H-pyran-2-yl) oxy) -1,14-ecosadienal and (S) -p-tolylsulfonylacetic acid tert -butyl ester as starting materials;

Gd) (R, Z) -3-Hydroxy- [(R) -p-tolylsulfinyl] -1-eicosenoic acid tert-butyl ester, Mass Spectrum: 464 (M)⁺-isobutylene),

IR spectrum:

403, 1 727, 1 596, 1 494, 1 145,

043 cm '¹starting from 9-octenal and (R) -p-tolylsulfonylacetic acid tert-butyl ester;

(3S, 5R.Z) -3-Hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] -2 - [(S) -p-tolylsulfinyl-13-docosenoic acid] tert -butyl ester from (R, Z) -3 - [(tetrahydro-2H-pyran-2-yl) oxy] -11-eicosenal and (S) -p-tolylsulfinylacetic acid tert -butyl ester as starting materials;

Gf) (? S) - (Miydroxy-p-phenoxy-α - [(R) -p-tolylsulphinyl] hydrocinnamic acid tert-butyl ester, m.p. 126-128 ° C (from n-hexane) from p-phenoxybenzaldehyde; and (R) -p-Tolylsulfinylacetic acid tert -butyl ester as starting materials;

Gg) (3S, 5S) -3-Hydroxy-5- (p-phenoxyphenyl) -5 - [(tetrahydro-2H-pyran-2-yl) oxyl] -2 - [(S) -p-tolylsulfinyl] tert -butyl ester m.p. 140-145 ° C, from (3) -p-phenoxy-p - [(tetrahydro-2H-pyranyljoxy) hydroscinnamic aldehyde and (S) -p-tolylsulfinylacetic acid tert -butyl ester as starting materials.

H. Preparation of Alcohols of Formula XIII g A 55% sodium hydride dispersion was washed with hexane and then 600 mL of tetrahydrofuran was added. A solution of 18.9 g of 2-acetyloctanoic acid methyl ester in 80 ml of tetrahydrofuran is then added dropwise with cooling. After stirring for two hours, the reaction mixture was cooled to -10 ° C and 65 mL of butyllithium (1.6 M in hexane) was added under cooling. After 1 hour at -10 ° C, a solution of 19.7 g of dodecanal in 80 ml of tetrahydrofuran is added dropwise. The reaction mixture was allowed to warm to room temperature and further stirred for 2 hours. The reaction mixture was hydrolyzed with 100 ml of 2N hydrochloric acid solution and evaporated. The residue is extracted with ether and the ether phase is dried and evaporated. Chromatography on silica gel gave 2-hexyl-5-hydroxy-3-oxohexadecanoic acid methyl ester, m.p. 38-39 ° C.

I. Preparation of Aldehydes of Formula VIII

and)

9.2 g of (R) -3 - [(tetrahydro-2H-pyran-2-yl) oxy] tetradecanoic acid tert-butyl ester are dissolved in 115 ml of toluene under argon atmosphere and moisture is eliminated and the solution is cooled to - 75 ° C. 26.5 ml of a 1.2 M solution of dilsobutylaluminium hydride in toluene are added dropwise to the solution so that the temperature does not exceed -70 ° C. After stirring at -75 ° C for 1 hour, 7.4 mL of saturated aqueous ammonium chloride solution was added dropwise, followed by 15.5 mL of 1 N hydrochloric acid solution at -70 ° C. The reaction mixture was then allowed to warm to room temperature. After stirring for 1 hour, the organic phase is dried, filtered

2β and the filtrate is evaporated. The residue is chromatographed on silica gel. (Rj-3 - [(tetrahydro-2H-pyra) was obtained^andn-2-yl) oxy] tetradecanol as a colorless oil.

The following compounds were prepared in an analogous manner:

Ib) rac.-3 - [(tetrahydro-2H-pyran-2-yl) oxy] tetradecanal from rac.-3 - [(tetrahydro-2H-pyran-2-yl) oxy] tetradecanoic acid methyl ester starting material;

(11Z.14Z) -3 - [(tetrahydro-2H-pyran-2-yl) oxy] -1,14-eicosadiene, mass spectrum: 291 (M) ^h-2-tetrahydropyranyloxy),

290 (M + -tetrahydro-2-pyranol)

IR spectrum:

729, 1,726, 1,132, 1,118, 1,077 cm -1¹;

from (11Z, 14Z) -3 - ((tetrahydro-2H-pyran-2-yl) oxyl-11,14-eicosadienoic acid tert-butyl ester) starting material;

(1d) (R, Z) -3 - [(tetrahydro-2H-pyran-2-yl) oxy] -11-eicosanal, mass spectrum:

292 (M⁺-tetrahydro-2-pyranol),

IC spectrum:

722, 1,726, 1,132, 1,118, 1,077 cm ”¹starting from (R.Z) -3 - [(tetrahydro-2H-pyran-2-yl) oxy] -1-eicosanoic acid tert-butyl ester;

1e) (3S) -β-phenoxy- [S] - [[tetrahydro-2H-pyran-2-yl] -oxyl cinnamic aldehyde from [(S) -p-phenoxy - N - [(tetrahydro-2H-pyran- 2-yl) oxy] benzyl] acetic acid starting material;

1f) (R) -3 - [(tetrahydro-2H-pyran-2-yl) oxy] -6Z-tetradecenal from (R) -3 - [(tetrahydro-2H-pyran-2-yl) oxy] tetradece ethyl ester. new acids as starting materials.

J. Production of Formula XV

I)

66.5 g of tert-butyl (R, 11Z, 14Z) -3-hydroxy-11,14-eicosadienoic acid, which contains about 20% of the (S) -isomer, and 32 ml of freshly distilled 3,4-dihydro- The 2H-pyran was dissolved in 650 mL of methylene chloride and the methylene chloride solution was cooled to 3 ° C. 640 mg of p-toluenesulfonic acid monohydrate are then added, raising the temperature to 8 ° C. The reaction mixture was stirred until the reaction was complete. The solution was then washed with a mixture of 250 ml of saturated aqueous sodium chloride solution, 250 ml of saturated aqueous sodium bicarbonate solution and 500 ml of water. After drying, the reaction mixture was filtered and the solvent was removed. The oily residue was purified by silica gel chromatography. A mixture of diastereoisomers of (11Z, 14Z) -3 - [(tetrahydro-2H-pyran-2-yl) oxy] -11,14-eicosadienoic acid tert-butyl ester is obtained.

Mass spectrum:

324 (M⁺-dihydropyran-isobutylene),

IC spectrum:

731, 1158, 1024 .cm '¹.

The following compounds are obtained in an analogous manner:

(B) (R, Z) -3 - ([tetrahydro-2H-pyran-2-yl) oxy] -11-eicosenoic acid tert-butyl ester, mass spectrum:

326 (M⁺(dihydropyran-iso-butylene),

IC spectrum:

731, 1158, 1134, 1118 cm '¹starting from (R, Z) -3-hydroxy-1-eicosenoic acid tert-butyl ester and dihydropyran;

{(S-p-phenoxy-af (tetrahydro-2H-pyran-2-yl) oxy) benzyl] acetic acid tert-butyl ester, mass spectrum:

313 (.M⁺-tetr ahydr opyrany 1),

IC spectrum:

730, 1 590, 1 506, 1 489, 1 391, 1 367,

201, 114-9 and 1119 cm⁺¹,

Rac. -3- [(tetrahydro-2H-pyran-2-yl) oxy] tetradecanoic acid methyl ester, silica gel thin layer chromatography (solvent system: 3: 1 hexane / ether) R_Ř = 0.67, starting from rac-3-hydroxytetradecanoic acid methyl ester and dihydropyran;

2-Hexyl-3-oxo-5 [(tetrahydro-2H-pyran-2-yl) oxy] hexadecanoic acid methyl ester, m.p. 37-38 ° C, from 2-hexyl-5-hydroxy-3 methyl ester oxohexadecanoic acid and dihydropyran starting materials;

K. Production of ester of formula XV (another variant)

Ka) '' '......

To a solution of 0.51 g of diisopropylamine in 20 ml of tetrahydrofuran at 0 ° C was added 3.13 ml of a 1.6 M solution of butyllithium in hexane. The reaction mixture was then cooled to -78^qC and 2.3 g of heptyltriphenylphosphonium bromide are added and the mixture is left at this temperature for 5 minutes. A solution of 5-formyl- (R) -3 - [(tetrahydro-2H-pyran-2-yl) oxy] pentanecarboxylic acid ethyl ester in 10 mL of tetrahyidrofuran was then added dropwise. The reaction mixture was allowed to stir overnight at room temperature. Water was then added to the reaction mixture, extraction was performed with ether, the ether extract was dried and evaporated in vacuo. The residue was chromatographed on silica gel using toluene / ethyl acetate 9: 1 as the eluent. 0.5 g of (R) 3 - [(tetrahydro-2H-pyrazin-2-yl) oxy] -6Z-tetradecenecarboxylic acid ethyl ester is obtained.

The following compound is obtained in an analogous manner:

Kb).

(R) -3 - [(tetrahydro-2H-pyran-2-yl) oxy] -6Z-eicosecarboxylic acid ethyl ester.

L. Production of an aldehyde of formula (XIX)

A solution of 2.56 g of (R) -3 - [(tetrahydro-2H-pyran-2-yl) oxy] -6-heptenoic acid methyl ester in 40 mL of ethyl acetate was treated with ozone at -75 ° C. After completion of the reaction, 0.1 g of palladium on carbon is added and hydrogenation is carried out at room temperature. After completion of the hydrogen uptake, the catalyst was filtered off, washed with ethyl acetate and the filtrate was evaporated in vacuo. Crude 5-formyl- (R) -3 - [(tetrahydro-2H-pyran-2-yl) oxy] pentanecarboxylic acid methyl ester was obtained.

M. Separation of acids of formula V into their stereoisomers

Ma)

Dissolve 15.4 g of a mixture of 2-hexyl-3-hydroxy- (R) -5 - [(tetrahydro-2H) -pyran-2-yl) oxy] hexadecanoic acid diastereomers in 160 ml of ethanol and add 800 ml of the solution obtained. mg of toluene-4-sulfonic acid monohydrate. The reaction mixture is heated to 55-60 ° C until the reaction is complete. The solvent was then removed in vacuo and the residue was dissolved in 160 ml of dichloromethane. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was then evaporated. The product obtained is chromatographed on silica gel. Tetrahydro-3-hexyl-4-hydroxy-R-6-undecyl-2H-pyran-2-one is obtained, m.p. 95-96 ° C.

Mb) g of a mixture of tetrahydro-3-hexyl-4-hydroxy- (R) -6-undecyl-2H-pyran-2-one diastereomers is dissolved in 300 ml of acetone. Thereafter, 3 ml of Jones reagent was added dropwise to the obtained solution while stirring so that the temperature did not exceed 25 ° C. After 3 hours, the reaction mixture is poured onto 700 ml of water. The lakitone precipitates and is filtered off. Recrystallization from ether-n-hexane gave 1.7 g of tetraihydro-3-hexyl-4-oxo- (R) -6-undecyl-2H-pyran-2-one, m.p.

113.5 ° C.

Mc) g of a mixture of tetrahydro-3-hexyl-4-oxo- (R) -6-undecyl-2H-pyran-2-one isomers is dissolved in 2 liters of ethyl acetate and 3 g of platinum oxide are added to the obtained solution. The reaction mixture was then hydrogenated for 12 hours at 50 psi hydrogen. The catalyst was filtered off and the solution was evaporated. Recrystallization gave 7 g of (3S, 4S, 6R) -tetrahydro-3-hexyl-4-hydroxy-6-undecyl-2H-pyran-2-one, m.p. 108-109 ° C.

Md) 1.5 g of (3S, 4S, 6R) -tetrahydro-3-hexyl-4-hydroxy-6-undecyl-2H-pyran-2-one is dissolved in 8 ml of dimethylformamide. 0.85 g of t-butyldimethylchlorosilane in 4 ml of dimethylformamide is then added dropwise. The reaction mixture was stirred for 48 hours. The reaction mixture was then poured into 100 ml of ether and washed with 1N hydrochloric acid. The organic phase was dried, filtered and evaporated. The product obtained is chromatographed on silica gel. 1.26 g of (3S, 4S, 6R) -tetrahydro-3-hexyl-4 - [(tert-butyldimethylsilyl) oxy] -6-undecyl-2H-pyran-2-one is obtained, mass spectrum:

411 (M⁺-terc.butyl).

Me) 0.3 g of (3S, 4S, 6R) -tetrahydro-3-ihexyl-4 - [(tert-butyldimethylsilyl) oxy] -6-undecyl-2H-pyran-2-one is dissolved in a mixture of 12 ml of dioxane and 0.64 ml of 1N aqueous · potassium hydroxide solution. The reaction mixture was stirred overnight. The reaction mixture was evaporated and the residue was dissolved in 10 ml of hexamethylphosphoric triamide. 0.35 ml of benzyl bromide is added to the obtained solution. The reaction mixture was stirred for 2 days. The reaction mixture was then poured into water and extracted with ether. The ether phase was dried, filtered and the filtrate was evaporated. The oil obtained is chromatographed on silica gel. 330 g of (2S, 3S, 5R) -2-hexyl-3 - [(tert-butyldimethylsilyl) oxy] -5-hydroxyhexadecanoic acid benzyl ester is obtained.

Mass spectrum:

519 (M⁺-terc.butyl).

Mf) 350 mg of (2S, 3S, 5R) -2-hexyl-3 - [(tert-butyldimethylsilyl) oxy] -5-hydroxyhexadecanoic acid benzyl ester and 0.5 ml of freshly distilled 3,4-dihydro-2H-₎The pyran was dissolved in 10 mL of methylene chloride and the methylene chloride solution was cooled to -15 ° C. Then, the p-toluenesulfonic acid monohydrate crystal is added. The reaction mixture is stirred until the reaction is complete. The solution was evaporated and the residue was chromatographed on silica gel. 330 mg of (2S, 3S, 5R) -2-hexyl-3 - [(tert-butyldimethylsilyl) oxy] -5 - [(tetrahydro-2H-pyran-2-yl) oxy] Jihexadecanoic acid benzyl ester is obtained.

Mass spectrum:

603 (M ⁺ -terc.butyl).

Mg) 480 mg of (2S, 3S, 5R) -2-hexyl-3 - [(tert-butyldimethylsilyl) oxy] -5 - [(tetrhydro-2H-pyran-2-yl) oxy] hexadecanoic acid benzyl ester and 350 mg of tetrabutylammonium fluoride was dissolved in 8 ml of tetrahydrofuran and the solution was stirred for 12 hours. After evaporation, the residue was dissolved in 50 ml of ethyl acetate and the ethereal solution was washed with water. The ether phase is dried and evaporated. The crude product is chromatographed on silica gel. 240 mg of (2S, 3S, 5R) -2-hexyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] hexadecanoic acid benzyl ester is obtained.

Mass spectrum:

463 [M + H]⁺-dihydro-2H-pyran-2-yl].

Mh) To 430 mg of (2S, 3S, 5R) -2-hexyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] hexadecanoic acid benzyl ester in 10 ml of tetrahydrofuran was added 10% palladium on The mixture was hydrogenated for 3 hours. Then, the catalyst is filtered off, the filtrate is evaporated and the crude product is chromatographed on silica gel. There was thus obtained (2S, 3S, 5R) -2-hexyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] hexadecanoic acid.

Preferred oxethanones of the general formula Г are those in which

R¹ means:

methyl, propyl, hexyl, decyl, heixadecyl, allyl, benzyl or especially ethyl,

R² means:

methyl, undecyl,

3-butenyl, 3-undecenyl, 8,11-heptadecadienyl, phenoxyphenyl or especially heptadecyl,

R³ represents an acetyl group or especially a formyl group,

R⁴ represents a methyl group or, in particular, a hydrogen atom, and

R⁵ means:

a hydrogen atom, a methyl group, a 2-butyl group, a benzyl group, a methylthioethyl group or in particular an isobutyl group, or

R⁴ together with R⁵ forms a pyrrolidinyl group.

Examples of such compounds include:

N-formyl-L-leucine 1 - [(trans-3-ethyl-4-oxo-2-oxetanyl) methyl] dodecyl ester,

N-formyl-L-leucine 1 - [(trans-3-allyl-4-oxo-2-oxetanyl) methyl] dodecyl ester, [S, 9Z, 12Z] -1- | N-formyl- (S) -leucine [(2S, 3S) -3-ethyl-4-oxo-2-oxetanyl] methyl-9,12-octadecadienyl ester, (S, Z) -1 - [[(2S, N-formyl- (S) -leucine, 3-ethyl-4-oxo-2-oxetanyl] methyl-9-octadecenyl ester, (R) -oH [(2S, 3S) -3-ethyl-4-oxo- N-formyl- (S) -leucine 2-oxethanes 1-methyl-p-phenoxybenzyl ester.

A particularly preferred compound is:

N-formyl- (S) -leucine (S) -1-i [(2S, 3S) -3-ethyl-4-oxo-2-oxetanyl] methyl ioctadecyl ester.

The oxethanones of the general formula (Г) have valuable pharmacological properties. Thus, in particular, they inhibit the pancreatic lipase and can be used accordingly in the treatment or prevention of obesity, hyperlipaemia, atherosclerosis and atherosclerosis.

Suppression of the pancreatic lipase of the oxethanes of the general formula (Г) can be demonstrated experimentally by titrometrically detecting oleic acid released by the pancreatic pancreatic lipase cleavage of triolein. An emulsion containing 1 mmol of taurodeoxycholate, 9 mmol of taurocholate, 0.1 mmol of cholesterol, 1 mmol of egg lecithin, 15 mg / ml BSA, 2 mmol of tris-HCl, 100 mmol of sodium chloride, 1 mmol of calcium chloride and

Table Substrate containing triolein, add the compound of formula Г dissolved in ethanol or dimethylsulfoxide (10% emulsion volume) and start the reaction by adding 100 µg of pancreatic lipase.

The pH is maintained at 8 by the addition of sodium hydroxide during the reaction. The IC 50 value is calculated from the sodium hydroxide consumption over 10 minutes. The IC50 is the concentration at which lipase activity is suppressed to one-half. The following tables contain the IC50 values ​​found for compounds of formula Г and acute toxicity data (toxicity after single oral administration to mice).

Test compound of Example

IC50

Toxicity (mg / kg) po

<td>(lb)</td><td colspan="2"> 19</td>

<td>2, 13a)</td><td> 0,007</td><td></td>

<td> 2, 14</td><td> 0,015</td><td> 5 000</td>

<td> 2, 21</td><td> 0,02</td><td></td>

<td>2, 23a)</td><td> 0,035</td><td></td>

<td>2, 25a)</td><td> 0,01</td><td> 2 000</td>

<td> 2, 34</td><td> 0,13</td><td></td>

<td> 4, 1</td><td> 0,11</td><td></td>

<td> 5</td><td> 0,20</td><td> 4 000</td>

<td> 6, 2</td><td> 1,0</td><td></td>

<td> 7</td><td> 15</td><td></td>

<td>9, F „2</td><td> 85</td><td></td>

The oxetanones of the general formula Г can be used as medicaments, for example in the form of pharmaceutical preparations. The pharmaceutical preparations may be administered orally, for example in the form of tablets, coated tablets, dragees, hard and soft gelatin capsules, solutions, emulsions or suspensions.

For the manufacture of pharmaceutical preparations, the compounds produced by the process of the invention may be formulated together with pharmaceutically inert, inorganic or organic carriers. As such carriers, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or salts thereof and others can be used for tablets, coated tablets, dragees and hard gelatine capsules. For soft gelatine capsules, suitable carriers are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the state of the active substance, however, no carrier substances are required at all for soft gelatine capsules. They are suitable for the production of solutions and syrups as carriers, for example, water, polyols, sucrose, invert sugar, glucose and the like.

The pharmaceutical preparations may additionally contain preservatives, co-solvents, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavoring agents, salts for varying the osmotic pressure, buffers, coating agents or antioxidants. Furthermore, the compositions may also contain other therapeutically valuable substances.

As mentioned above, the present invention also relates to medicaments comprising oxetanone of the formula Г. The present invention also relates to a process for the preparation of such medicaments, which comprises mixing oxetanone of the formula popřípadě and optionally one or more therapeutically valuable substances and converting the mixture to galenic form.

As mentioned above, the compounds of formula (I) may be used in the treatment or prevention of diseases, in particular in the treatment or prevention of obesity, hyperlipemia, atherosclerosis and arteriosclerosis. The dosage of the active ingredient can vary within wide limits and naturally adapts to the individual circumstances in each individual case. In general, in particular when administered orally, the daily dose may be from about 0.1 mg to 100 mg / kg body weight.

The oxethanones of the general formula Г can also be added to industrially prepared foods, in particular fats, oils, butter, margarine, chocolate and other sweets. Accordingly, the present invention also relates to such industrially produced foods containing about 0.1 to 5% by weight of oxethanone of general formula Г as well as their preparation.

The following examples serve to illustrate the present invention in more detail. However, these examples do not limit the scope of the invention in any way.

6 2 4 2 5

Example 1

To a solution of 100 mg rac.-3-hexyl-4- (2-hydroxytriclecyl) -2-oxetanone (2R, 3S, 4S: 2S, 3R, 4R), 74 mg triphenylphosphine and 45 mg N-formyl-D-leucine in 2 ml of tetrahydrofuran is added dropwise with stirring, 44.3 ml of azodicarboxylic acid diethyl ester. After stirring overnight, the organic phase was evaporated in vacuo and the residue removed. after evaporation, it is purified by chromatography on silica gel, eluting with toluene / ethyl acetate (9: 1). The following are obtained:

1a) N-formyl-D-leucine (R) 1 - {[(2R, 3R) -3-hexyl-4-oxo-2-oxetanyl] methylidodecyl ester (R);

[a] o²⁰ + 34.4 ° (c = 1, in chloroform) -a

(lb)

N-formyl-D-leucine 1-N [(2S, 3S) -3-hexyl-4-oxo-2-oxetanyl] methylidodecyl ester (S);

[α] π^2ϋ - 4-2.2 ° (c = 0.9, in methanol).

Example 2

The following compounds are obtained in an analogous manner:

2.1) esterification of rac-3-hexyl-4- (2-hydroxytridecyl) -2-oxethanone (2R, 3R, 4R: 2S, 3S, 4S) with N-formyl-D-leucine gives:

2.1a)

N - formyl-D-leucine dodecyl ester (S) - 1 - [(2R, 3R) -3-hexyl-4-oxo-2-oxetanyl] methyl;

Okay²⁰ = 4-19.4 ° (c = 0.35, in methanol)

2.1b) N-formyl-D-leucine ([R]) - [(2S, 3S) -3-hexyl-4-oxo-2-oxetanyl] -methyl-dodecyl ester (R);

[α) ι?^ϋ = 4-2.8 ° (c = 0.8, in methanol);

2.2) esterification of rac.-3-hexyl-2- (2-hydroxytridecyl) -2-oxethanone (2S, 3R, 4R: 2R, 3S, 4S) with N-formyl-L-leucine yields:

N-formyl-D-leucine (R) 1 - [(2R, 3R) -3-hexyl-4-oxo-2-oxetanyl] methyl / dodecyl ester;

[d] d²⁵ = -2.2 ° (c = 0.9 ° / o, in methanol);

2.3) esterification of rac.-3-hexyl-4- (2-hydroxytridecyl) -2-oxethanone (2S, 3S, 4S: 2R, 3R, 4R) or (3R, 4R) -3-hexyl-4 - [(R) (24-Hydroxytridecyl) -2-oxethanone] N-formyl-L-leucine gives:

2.3 a) N-formyl-L-leucine (R) - [(23,3S) -3-hexyl-4-oxo-2-oxetanyl] methyl] dodecyl ester (R);²⁵ = -19.4 ° (methanol, c = 0.35%) a

2.3'b) N-formyl-L-leucine (S) 1 - [[(2R, 3R) -3-hexyl-4-oxo-2-oxetanyl] methylphidodecyl ester (S), [ar]₌- 2.87 ° (methanol, c = 0.8%);

2.4) esterification of rac-3-hexyl-4- (2-hydroxytridecyl) -2-oxetoune (pair of enantiomers A) with N-formyl-L-leucine gives:

2.4a)

N - [(cis-3-hexyl-4-oxo-2-oxetanyl) methyl] dodecyl ester of N-formyl-L-leucine, thin layer chromatography on silica gel (solvent system: toluene / ethyl acetate 2: 1), R_F = 0.55 a

2.4b)

1 - [(cis-3-hexyl-4-oxo-2-exetanyl) methyl] dodecyl N-formyl-L-lucine ester, silica gel thin layer chromatography (solvent system: toluene / ethyl acetate 2: 1), R_F = 0,47;

2.5) by racialization of rac-3-hexyl-442-hydroxytridecyl-2-oxetanone (pair of enantiomers B) with N-formyl-L-leucine:

2.5 a) M-formyl-L-leucine 1 - [(cis-3-hexyl-4-oxo-2-oxetariyl) methyl] dodecyl ester, silica gel thin layer chromatography (solvent system: toluene / ethyl acetate 2: 1) ), R_F = 0.53 .a

2.5 b)

N - [(cis-3-hexyl-4-oxo-2-oxetanyl) methyl] dodecyl ester of N-formyl-L-leucine, thin layer chromatography on silica gel (solvent system: toluene / ethyl acetate 2: 1), R_F = 0,50;

<img file="CS262425B2_D0014.tif" />

2.6) esterification of (3S, 4S) -3-hexyl-4 - [(R) -2-hydroxytridecyl] -2-oxethanone with N-formylglycine affords:

N- (2S, 3S) - [(3-hexyl-4-oxo-2-oxetanyl) methyl] dodecyl ester of N-formyl- (SJ-glycine, [or] n)²⁵ = -22 ° (chloroform, c = 0.88);

2.7) esterification of trans-3-hexyl-4- (2-hydroxytridecyl) -2-oxethanone with N-formylglycine:

N - formylglycine 1 - [(trans-3-hexyl-4-oxo-2-oxetanyl) methyl] dodecyl ester, thin layer silica gel (solvent system: diethyl ether / hexane 9: 1), R_Ř — 0,34;

2.8) esterification of rac.-3-Liexyl-4- (2-hydroxytridecyl) -2-oxethanone [2R, 3S, 4S: 2S, 3R, 4R) by N-acetyl-L-leucine gives:

N - acetyl - L - deucine 1 - [(trans-3-hexyl-4-oxo-2-oxetanyl] methyl] dodecyl ester, thin layer chromatography on silica gel (solvent system: chloroform / hexane / dioxane 1: 3: 0, 25), R_F = 0,36;

2.9) esterification of [3S, 4S] -3-hexyl-4 - [(R) 2-hydroxytridecyl] -2-oxethanone with N-formyl-4-alanine gives:

1- (2S, 3S) - [(3-hexyl-4-oxo-2-oxetanyl) methyl] dodecyl ester of N-formyl- / 3-alanine (S), thin layer chromatography on silica gel (solvent system: toluene / ethyl acetate in ratio 2: 1) Rf_F — 0,39;

2.10) esterification of trans-3-hexyl [(S) -2-hydroxypropyl] -2-oxethanone (3S, 4S: 3R, 4R) with N-formyl-L-leucine gives:

N-formyl-L-leucine (S) 1 - [(3-hexyl-4-oxo-2-oxoanyl) methyl] ester, silica gel thin layer chromatography (solvent system: toluene / ethyl acetate 2) : 1), R_F = 0,27;

2.11) esterification of 3-methyl-4 - [(R) -2-hydroxytridecyl] -2-oxethanone (3R, 4R: 3S, 4S) with N-formyl-L-leucine gives:

N - formyl-L-leucine (S) 1 - [(3-methyl-4-oxo-2-oxetanyl) methyl] dodecyl ester, thin layer chromatography on silica gel (solvent system: toluene / ethyl acetate 2: 1), R_F = 0,34;

2.12) esterification of rac-trans-3-hexadecyl-4- (2-hydroxypropyl) -2-oxethanone with N-formyl-L-leucine gives:

1 - [(trans-3^JN-formyl-L-leucine hexadecyl-4-oxo-2-oxetanyl) methyl] ethyl ester, mass spectrum: 496 (M⁺ ); thin layer chromatography on silica gel (solvent system: toluene / ethyl acetate 2: 1), R_Ř = 0,44;

2.13) esterification of rac.-trans-3-ethyl-4- (2-hydroxytridecyl) -2-oxethanone with N-formyl-L-leucine gives:

2.13a)

N - formyl-L-leucine 1 - [(trans-3-ethyl-4-oxo-2-oxetanyl) methyl] dodecyl ester, thin layer chromatography on silica gel (solvent system: toluene / ethyl acetate 2: 1), R₍ = 0,62;

2.13b)

N - formyl-L-leucine 1 - [(trans-3-ethyl-4-oxo-2-oxetanyl) methyl] dodecyl ester, thin layer chromatography on silica gel (solvent system: toluene / ethyl acetate 2: 1), R_F = 0,55;

2.14) esterification of rac.-trans-3-allyl-4- (2-hydroxytridecyl) -2-oxetanone with N-formylleucine gives:

N-formyl-L-leucine 1 - [(trans-3-allyl-4-oxo-2-oxetanyl) methyl] dodecyl ester,

IR spectrum:

825, 1739, 1688 cm '¹TLC on silica gel (solvent system: toluene / ethyl acetate 2: 1) R_F = 0,58;

2.15) esterification of rac-4rans-3-hexyl-4- (2-hydroxy-tridecyl) -2-oxethanone with N-benzylcarbamoylleucine gives:

benzylcarbamoylleucine N 1 - [(traiis-3-hexyl-4-oxo-2-oxetanyl) methyl) dodecyl ester, thin layer chromatography on silica gel (solvent system: hexane / diethyl ether 1: 1), Rf = 0 , 64;

2.16) esterification of (3S, 4S) -3-hexyl-4 - [(R, 10Z, 13Z) -2-hydroxy-10,13-nonadecadienyl] -2-oxetanone with N-formyl- (S) -leucine gives:

N-formyl- (S) -leucine- (S, 9Z, 12Z) 1 - [(2S, 3S) -3-hexyl-4-oxo-2-oxetanyl] methyl 9,12-octadienyl ester, mass spectrum: 575 (M⁺),

IR spectrum:

824, 1739, 1667 cm⁴;

2.17) esterification of rac.-trans-3-hexyl-4 - [(10Z, 13Z) -2-hydroxy-10,13-nonadecadienyl] -2-oxethanone (2R, 3R, 4R: 2S, 3S, 4S) N- formyl- (S) -leucine is obtained by:

N-formyl- (S) -leucine [9Z, 12Z] 1- [trans-3-hexyl) -4-oxo-2-oxetanyl) methyl] octadecadienyl ester [9Z, 12Z] (2-diastereomers), mass spectrum: 575 (M) ¹ ),

IR spectrum:

824, 1740, 1687 cm⁴;

2.18) esterification of cis-3-hexyl-4 - [(10 Z, 13 Z) -2-hydroxy-1 H, 13-nonadecadienyl] -2-oxethanone (mixture of diastereomers) with N-formyl- (S) -leucine gives:

2.18 a)

N-formyl- (S) -leucine (9Z, 12Z) 1 - [(cis-3-hexyl-4-oxo-2-oxanyl) methyl] -9,12-octadienyl ester (mixture of diastereomers I), by weight Spectrum: 575 (M +),

IR spectrum:

1823, 1739, 1674 cm⁴ and

2.18ib)

N - formyl- (S) -leucine (9Z, 12Z) 1 - [(cis-3-: hexyl-4-oxo-2-oxetanyl) methyl] -9,12-octadienyl ester (mixture of diastereomers II), mass spectrum:

372 (M ⁺-N-formyl-leucine-CO 2),

IC spectrum:

822, 1,739, 1,684 СПГ¹;

2.19) esterification of (3S, 4S) -3-benzyl-4 - [(R, 10Z, 13Z) -2-hydroxy-10,13-nonadecadienyl)] -2-oxethanone with N-formyl- (S) -leucine gives :

N-formyl- (S) -1, eucmu 1-{[(2S, 3S) -3-benzyl-4-oxo-2-oxoananyl] methyl | -9,12-octadienyl ester (S, 9Z, 12Z) Mass Spectrum: 581 (M &amp; lt; + &amp; gt;)¹),

IC spectrum:

825, 1739, 1683 cm '¹;

2.20) esterification of rac.-trans-3-ibenzyl-4 - [(10Z, 13Z) -2-hydroxy-10,13-nonadecadienyl] -2-oxethanone (2R, 3R, 4S: 2S, 3S, 4S) N- formyl- (S) -leucine is obtained by:

2.20a)

N-formyl- (trans-3-benzyl-4-oxo-2-oxetanyl) methyl] -9,12-octadecadienyl ester

- (S) -leucine (9Z, 12Z) mixture of diastereomers 1), mass spectrum: 581 (M)⁺),

IC spectrum:

825, 1739, 1676 cm '¹ and

2.20b)

N-formyl- (trans-3-benzyl-4-oxo-2-oxetanyl) methyl] -9,12-octadecadienyl ester

- (S) -leucine (9Z, 12Z) mixture of diastereomers Π), mass spectrum: 581 (M)⁺),

IC spectrum:

824, 1,740, 1,687 cm '¹;

2.21) esterification of trans-3-ethyl-4 - [(10Z, 13Z) -2-hydroxy-10β-nonadecadienyl] -2-oxethanone (mixture of diastereomers) with N-formyl- (S) -leucine is obtained :

N-formyl- (S) -leucine (S, 9Z, 12Z) 1 - {[(2S, 3S) -3-ethyl-4-oxo-2-oxetanyl] methyl-9,12 octadecadienyl ester, mass spectrum: 519 (M⁺),

IC spectrum:

1825, 1739, 1684 cm '¹;

2.22) esterification of cis-3-ethyl-4 - [(10, Z, 13Z) -2-hydroxy-10,13-nonadecadienyl] -2-oxethanone with N-formyl- (S) -leucine (mixture of enantiomers B) gives :

1 - [(cis-3^:N-formyl (S) -leucine (9Z, 12Z) (4-oxo-2-oxetanyl) methyl] -9,12-octadecadienyl ester (9Z, 12Z) (mixture of diastereomers), mass spectrum:

316 (M⁺-N-formyl-leucine-CO2);

IC spectrum:

825, 1,739, 1,677 cm *¹;

2.23) esterification of (3S, 4S) -3-ethyl-4 - [(R, Z) -2-hyd-. roxy-10-nonadecenyl] -2-oxethanone with N-formyl-S-leucine gives:

N-formyl- (S) -leucine (S, Z) 1- (1S, 3S) -3-ethyl-4-oxo-2-oxetanyl] methyl | -9-octadecenyl ester (S, Z) (diastereomer I), mass spectrum: 521 (M¹)

IC spectrum:

1825, 1739, 1673 cm *¹, and

2.23b)

N-formyl- (S) -leucine (Z) 1 - [(trans-3-ethyl-4-oxo-2-oxoethanyl) methyl] -9-octadecenyl ester,

IC spectrum:

325, 1,825, 1,740, 1,685, 1190, 1,112 cm *¹;

2.24) esterification of (3S, 4S) -3-hexyl-4 - [(S) - [3-hydroxy-p-phenoxyphenethyl] -2-oxethanone with N-formyl- (S) -leucine gives:

N-formyl- (S) -leucine α- ', ((2S, 3S) -3-hexyl-4-oxo-2-oxetanyl] methyl) -β-phenoxybenzyl ester (mixture of diastereomers), mass spectrum: 509 (M⁺),

IC spectrum:

821, 1742, 1686 cm¹;

2.25) esterification of (3S, 4S) -3-ethyl-4- ((S) - (S) -hydroxy-p-enoxyphenethyl) -2-oxethanone with N-formyl- (S) -leucine gives:

2.25a) (R) - N-formyl- (S) -leucine ((2S, 3S) -3-ethyl-4-oxo-2-oxetanyl] methyl) - p-phenoxyibenzyl ester, mass spectrum: 453 (M⁺ ),

IC spectrum:

824, 1,742, 1,686 cm *¹, and

2.25b) (S) - N-formyl- (S) -leucine [(2S, 3S) -3-ethyl-4-oxo-2-oxetanyl] methyl-p-phenoxybenzyl ester, mass spectrum: 453 (M⁺),

IC spectrum:

823, 1,743, 1,686 cm *¹;

2.26) esterification of rac-trans-3-hexyl-4- (2-hydroxy-5-hexenyl) -2-oxethanone with N-formyl-L-leucine gives:

N-formyl-L-leucine 1 - [(trans-3-hexyl-4-oxo-2-oxetanyl) methyl] -4-pentenyl ester (mixture

2-diastereomers);

2.27) esterification of (S) -3-hexyl- (S) -4 - [(R) -2-hydroxy-5-hexenyl) -2-oxethanone with N-formyl-L-leucine gives:

1-N [(2S, 3S) -3-hexyl-4-oxo-2-oxetanyl] methyl N-formyl-L-leucine (4-pentylester) (S),

IC spectrum:

. 1,825, 1,740, 1,690 cm *¹;

mass spectrum: 396 (M + H) ⁺ ;

2.28) esterification of (S) -3-hexyl- (S) -4 - [(R) -2-hydroxy-5-hexenyl)] -2-oxethanone with N-formyl- (S) -valline gives:

1- | N-formyl- (S) -valine ((2S, 3S) -3-hexyl-4-oxo-2-oxetanyl] methyl) -4-pentenyl ester,

IC spectrum:

825, 1,740, 1,690 cm *¹;

Mass Spectrum: 382 (M + H) ⁺ ;

2.29) esterification of (S) -3-hexyl- (S) -4- ((R) -2-hyd262425-roxy-5-hexenyl) -2-oxethanone with N-formyl-L-isoleucine gives:

N-formyl-L-isoleucine (S) -1 - [(2S, 3S) -3-hexyl-4-oxo-2-oxothanyl] methyl-4-pentenyl ester,

IC spectrum:

823, 1735 and 1690 cm⁴; mass spectrum:

396 (M + H)⁺, 395 (M);

2.30) esterification of (S) -3-hexyl- (S) -4 - [(R) -2-hydroxy-5-hexenyl) -2-oxethanone with N-formyl-L-phenylalanine affords:

N-formyl-L-phenylalanine (S) -1-i [[2S, 3S) -3-hexyl-4-oxo-2-oxetanyl] methyl] -4-pentenyl ester,

IC spectrum:

825, 1740, 1690 cnv¹;

mass spectrum:

430 (M - | - H)⁴*, 429 (M);

2.31) esterification of (S) -3-hexyl- (S) -4 - [(R) -2-hydroxy-5-hexenyl) -2-oxethanone with N-formyl-L-alanine gives:

N-formyl-L-alanine (S) -1 - [(2S, 3S) -3-hexyl-4-oxo-2-oxetanyl] -4-pentenyl ester,

IC spectrum:

823, 1740, 1690 cm⁴;

Mass Spectrum: 354 (Μ ψ H)⁴;

2.32) esterification of the (S) -3-hexyl- (S) -4 - [(R) -2-hydroxy-5-hexenyl) -2-oxethanone of the N-form by 1-L-prolem gives:.

N-formyl-L-proline (S) -1 - [[(2S, 3S) -3-hexyl-4-oxo-2-oxothanyl] methyl-4-pentenyl ester,

IC spectrum:

825, 1740, 1690 cm⁴;

mass spectrum: 379 (M);

2.33) esterification of (S) -3-hexyl- [S) -4 - [(R, Z) -2-hydroxy-5-tridecenyl] -2-oxethanone with N-formyl-L-leucine gives:

N-formyl-L-leucine [S, Z) -1 - ([(2S, 3S) -3-hexyl-4-oxo-2-oxetanyl] methyl [-4-dodecenyl ester],

IC spectrum:

82: 5, 1735, 1690 cm⁴;

mass spectrum: 494 (MH) ⁺ ;

2.34) esterification of (S) -3-decyl- (S) -4 - [(R) -2-hydroxy-5-hexenyl] -2-oxethanone with N-formyl-L-leucine gives:

N-formyl-L-leucine (S) -1-; [(2S, 3S) -3-decyl-4-oxo-2-oxetanyl] methyl;

IC spectrum:

825, 1740, 1690 cm⁴;

mass spectrum: 451 (M);

2.35) esterification of (S) -3-hexyl- (S) -4 - [(R) -2-hydroxy-5-hexenyl] -2-oxethanone with N-formyl-L-methionine gives:

N-formyl-L-methionine (S) -1 - [[(2S, 3S) -3-hexyl-4-oxo-2-oxethanes] methyl] -4-ipentenyl ester,

IC spectrum:

820, 1735, 1685 cm⁴;

mass spectrum: 413 (M);

2.36) esterification of 3-ethyl-4 - [(10Z, 13Z) -2-hydroxy-10,13-nonadecadienyl-2-oxethanone with N-formyl-L-methyl-L-leucine yields:

N-formyl-N-methyl-L-leucine (9Z, 12Z) -1 - ((3-ethyl-4-oxo-2-oxetanyl) methyl) -9,12-octadienyl ester,

1C spectrum:

825, 1735, 1685, 1450, 1180 · cm⁴;

mass spectrum:

533 (M + 6), 316 (8), 174 (50), 128 (100).

Example 3

27 mg of N-formyl- (S) -leucine (S, 9Z, 12Z) -1 - [[(2S, 3S3-3-hexyl-4-oxo-2-oxetanyl) methyl} -9,12-octadienyl ester] 4.4 ml of 10% palladium on carbon are added in 1 ml of tetrahydrofuran, the reaction mixture is hydrogenated until the reaction is complete at room temperature, then the catalyst is filtered off and the solvent is removed in vacuo to give (S) -1. N-formyl- (S) -leucine [(2S, 3S) -3-hexyl-4-oxo-2-oxetanyl] methyl | octaidecyl ester as white crystals, m.p. 64-65 ^CC.

Example 4

The following compounds are obtained in an analogous manner to that described in Example 3:

4.1) from N-formyl- (S) -leucine (S, 9Z, 12Z) -1 - [[(2S, 3S) -3-ethyl-4-oxo-2-oxetanyl] methyl | -9,12-octadecadienyl ester is obtained:

N-formyl- (S) -leucine (S) -1 - [[(2S, 3S) -3-ethyl-4-oxo-2-oxetanyl] methyl octadecyl ester as white crystals, m.p. 48-53 ° C ;

4.2) From N - formyl-L-leucine 1 - [(trans-3-allyl-4-oxo-2-oxetanyl) methyl] dodecyl ester:

N-formyl-L-leucine 1 - [(trans-3-propyl-4-oxo-2-oxetanyl) methyl iodo ester,

IC spectrum:

825, 1740, 1690, 1523 cm '¹;

mass spectrum: 397 [М (СНз) 2СН2];

Example 5

To a solution of 10 mg of N-formyl-L-leucine 1 - [(trans-3-hexyl-4-oxo-2-oxetanyl) methyl] -4-pentenyl ester in 0.5 ml of tetrahydrofuran was added 2.5 mg of 5% palladium on carbon After the hydrogen uptake is complete, the catalyst is filtered off and the filtrate is evaporated in vacuo, and the residue is chromatographed on silica gel (toluene / ethyl acetate 8: 2). The amorphous 1 - [(trans-3-hexyl-4-oxo-2-oxetanyl) methyl] pentyl N-formyl-L-leucine ester is obtained as a mixture of 2 diastereomers. Silica gel thin layer chromatography: solvent system: toluene / ethyl acetate 8: 2, R-value_F = 0,15.

Example 6

The following compounds were obtained in an analogous manner to that described in Example 5:

6.1) From N-formyl-L-alanine (S) -1 - [[(2S, 3S) -3-hexyl-4-oxo-2-oxetanyl] methyl] -4-ipentenyl ester:

N-formyl-L-alanine (S) -1-N [(2S, 3S) -3-hexyl-4-oxo-2-oxothanyl] methyl] pentenyl ester,

IC spectrum:

820, 1,735, 1,680 cm ”¹, thin layer chromatography (silica gel, solvent system: 1: 1 ether / hexane), R-value_F = 0,06;

6.2) From N-formyl-L-phenylalanine (S) -1 - {[(2S, 3S) -3-hexyl-4-oxo-2-oxetanyl] methyl | -4-pentenyl ester:

N-formyl-L-phenylalanine (S) -1-N [(2S, 3S) -3-hexyl-4-oxo-2-oxetanyl] methyl-4-pentyl ester,

IC spectrum:

820, 1740, 1690 cm '¹, mass spectrum: 386 [MH2NCHO];

6.3) From N-formyl-L-leucine (S) -1-N [(2S, 3S) -3-decyl-4-oxo-2-oxetanyl] methyl-4-pentenyl ester, the following are obtained:

N-formyl-L-leucine (S) -1-J [(2S, 3S) -3-decyl-4-oxo-2-oxetanyl] methylpentyl ester,

IC spectrum:

823, 1739, 1676 cm '¹, mass spectrum: 397 (M).

Example 7

A solution of 67 mg of N-benzylcarbamoylleucine 1 - [(trans-3-hexyl-4-oxo-2-oxetanyl) methyldodecyl ester in 15 ml of tetrahydrofuran is hydrogenated in the presence of 10% palladium on carbon at room temperature under hydrogen (atmospheric pressure). After filtration of the catalyst, the filtrate is evaporated and the product is chromatographed on silica gel to give pure 1 - [(trans-3-hexyl-4-oxo-2-oxetanyl) methyl iododecyl ester of leucine, m.p. 30 T.

Example 8

265 mg of a mixture of diastereomers of 3-hexyl-4 [(10Z, 13Z) -2- (tetrahydro-2H-pyran-2-yl) oxy] -10,13-nonadecadienyl] -2-oxethanone is dissolved in 2.5 ml ethanol and to this solution was added 13 mg of pyridinium 4-toluenesulfonate. The reaction mixture is heated to 55-60 ° C until completion of the reaction. The solvent is then removed in vacuo and the residue is taken up in ether, whereupon crystals precipitate which are filtered off. The solvent is removed in vacuo and the residue is chromatographed on silica gel, eluting the products below. Partially contaminated products can be purified by repeating the chromatography. In this way:

8.1] (3S, 4S) -4-hexyl-4 - [(R, 10Z, 13Z) -2-hydroxy-10,13-nonadecadienyl] -2-oxetanone (dbastereomer I] as a colorless oil, mass spectrum: 434 (M +)

IC spectrum:

420, 1,820,111 cnr¹;

8.2) rac.-trans-3-hexyl-4 - [(10Z, 13Z) -2-hydroxy-10,13-nonadecadienyl] -2-oxethanone (diastereomer II) as a colorless oil, mass spectrum: 434 (M)⁺),

IC spectrum:

448, 1,830, 1,122 cm-¹;

8.3) cis-3-hexyl-4 - [(10Z, 13Z) -2-hydroxy-10,13-nonadecadienyl] -2-oxethanone (diastereomer III) as a colorless oil, mass spectrum: 434 [M¹ ),

IC spectrum:

374,1182,117 cm-¹.

Example 9

The following compounds were prepared in an analogous manner to that described in Example 8:

9.A.1) trans-3-ethyl-4 - [(10Z, 13Z) -2-hydroxy-10,13-nonadecadienyl] -2-oxethanone, mass spectrum:

360 (M + - H 2 O),

334 (M⁺—CO2),

316 (M + -. H2O-W2),

IC spectrum:

446, 1 823, 1 122 shots'¹;

9.A.2) cis-3-ethyl-4 - [(10Z, 13Z) -2-hydroxy-10,13-nonadecadienyl] -2-oxethanone (mixture of enantiomers A), mass spectrum: 378 / M¹,

IC spectrum:

445, 1822, 1116 cm '¹ and

9.A.3) cis-3-ethyl-4 - [(10Z, 13Z) -2-hydroxy-10,13-nonadecadienyl] -2-oxethanone (mixture of enantiomers B), mass spectrum:

(chemical induction with NH3):

396 (M + NH 4¹), 374 (M + H &amp; lt; + &amp; gt;),

IC spectrum:

415, 1 823, 1 115 cm¹;

from a mixture of cis, trans 3-ethyl-4 - [[(R, 10Z, 13Z) -2- (tetrahydro-2H-pyran-2-yl) oxy] -10,13-nonadecadienyl] -2-oxethanone;

9.B.

3-Ethyl-4 - [(2-hydroxy-γ-10-nonadecenyl) -2-oxethanone, mass spectrum:

362 (M + - H 2 O),

318 (M + —H2O — 102)

IC spectrum:

435, 1823, 1119 cm⁴from 3-ethyl-4- | (Z) -2 - [(tetrahydro-2H-, pyran-2-yl) oxy; -10-nonadecenyl-2-oxethanone;

9.C.1) (3S, 4S) -3-Benzyl-4 - ((R, 10Z, 13Z) -2-hydroxy-10,13-nonadecadienyl] -2-oxethanone, Mass Spectrum: 440 (M) ⁺ ),

IC spectrum:

430, 1822, 1120 cm⁴;

9.C.2) rac-trans-3-benzyl-4 - [(10Z, 13Z) -2-hydroxy-10,13-nonadecadieriyl] -2-oxethanone, mass spectrum: 440 (M)⁺),

IC spectrum:

512, 1822, 1123 cm⁴ and

9.C.3) cis-3-benzyl-4 - [(10Z, 13Z) -2-hydroxy-10 ', 13-nonadecadienyl] -2-oxetanone (2 diastereomers), mass spectrum:

378 (M ⁺—CO2 — H2O),

287 (M⁺, —H2O — CO2 — benzyl),

IC spectrum:

420, 1822, 1134 cm¹from a mixture of diastereomers of 3-benzyl-4 - [(R, 10Z, 13Z) -2- (tetrahydro-2H-pyran-2-yl) oxy] -10,13-nonadecadienyl] -2-oxethanone as a starting material;

9.D.

(35.45) -3-hexyl-4 [(S) -4-hydroxy-p-phenoxyphenethyl] -2-oxethanone, m.p. 51-54 ° C, mass spectrum: 368 (M) ⁺),

IR spectrum:

486, I 793, 1245, 1141;

starting from (3S, 4S) -3-hexyl-4 - {(S) -β-phenoxy- N - [(tetrahydro-2H-pyran-2-yl) oxy] phenethyl-2-oxethanone;

9.E.

(35.45) -3-ethyl-4 - [(S) -β-hydroxy-p-phenoxyphenethyl] -2-oxethanone, m.p. 67-70 ° C, mass spectrum: 312 [M]⁺ ),

IC spectrum:

416, 1 835, 1 250, 1 108 °¹;

from (3S, 4S) -3-ethyl-4- (S) -p-phenoxy-N - [(tetrahydro-2H-pyran-2-yl) oxy] phenethyl_l^l-2-o: ethanone as a starting material;

9.F.1) rac-trans-3-hexyl-4- (2-hydroxytridecyl) -2-oxethanone (2R, 3S, 4S: 2S, 3R, 4R), m.p. 44.5-40 ° C;

9.F.2) rac.-trans-3-hexyl-4- (2-hydroxytridecyl) -2-oxethanone (2S, 3S, 4S: 2R, 3R, 4R), m.p. 45.5-47 ° C ;

9.F.3) rac.-cis-3-hexyl-4- (2-hydroxytridecyl) -2-oxethanone (pair of enantiomers A), silica gel thin layer chromatography (solvent system: hexane / ethyl acetate 9: 1) ): R_F = 0.49 a

9.F.4) rac.-cis-3-hexyl-4- (2-hydroxytridecyl) -2-oxethanone (pair of enantiomers B), silica gel thin layer chromatography (solvent system: hexane / ethyl acetate 9: 1) ): R_F = 0,46;

starting from 3-hexyl-4- (2 - ((tetrahydro-2H-pyran-2-yl) oxy) tridecyl) -2-oxethanone;

9.G.1) (3S, 4S) -3-Hexyl-4 - [(R) -2-hydroxy-tridecyl] -2-oxethanone, m.p. 46-46.5 + a

9.G.2) (3R, 4R) -3-hexyl-4 - [(R) -2-hydroxytridecyl] -2-oxethanone, m.p. 46-47 ° C, [α] d²⁰ = + 12 ° (chloroform, c = 1.5);

from 3-hexyl-4- | (R) -2 - [(tetrahydro-2H-pyran-2-yl) oxy] tridecyl | -2-oxethanone as a starting material; in

9.H.

rac.-trans-3-ethyl-4- (2-hydroxytridecyl) -2-oxethanone, m.p. 35.5-36 ° C, from 3-ethyl-4- | 2 - [(tetrahydro-2H-pyran- 2-yl) oxy] tridecyl-2-oxetanone starting material;

9.1.

trans-3-methyl-4 - [(R) -2-hydroxytridecyl] -2-oxetanone, silica gel thin layer chromatography (solvent system: hexane / ether 1: 3): Rf = 0.49 from 3-methyl-4 - ((R) -2 - [(tetrahydro-2H-pyran-2-yl) oxy] tridecyl] -2-oxethanone as a starting material;

9.J.

rac.-trans-3-allyl-4- [2-hydroxytridecyl] -2-oxethanone, silica gel thin layer chromatography (solvent system: 1: 1 hexane / ether): Rf = 0.39, of 3- ally-4- (2 - [(tetrahydro-2H-pyran-2-yl) oxy] tridecyl] -2-oxethanone starting material;

9.K.

trans-3-hexyl-4 - [(R) -2-hydroxypropyl] -2-oxethanone, silica gel thin layer chromatography (solvent system: hexane / ether 1: 3): Rf = 0.36, of 3 -hexyl-4 - {(R) -2 - [(tetrahydro-2H-pyran-2-yl) oxy] propyl,^!-2-oxethanone as a starting material;

9.L.

trans-3 hexadecyl-4- (2-hydroxypropyl) -2-oxethanone, m.p. 37-38 ° C, from 3-hexadecyl-4- {2 - [(tetrahydro-2H-pyran-2)] -yl) oxy] propyl-2-oxethanone starting materials;

9.M.

rac.-trans-3-hexyl-4- [2-hydroxy-5-hexenyl] -2-oxethanone (2R, 3S, 4S: 2S, 3R, 4R), ^X1 H NMR Spectrum [dcuterochloroform]:

5.84 (in, 1H, —CH.dbd.CII2),

5.06 (m, 2H, - CH = Cl 12),

4.51 [double d, 1H, HC (4), J = 4.4 and 8 Hz],

3.87 [m, 1 H, CH (OH)],

3.26 [double d, 1H, HC (3), J = 4.7 and

8.5 Hz],

2.21 (m, 2H, CH2 --CH.dbd.CH2),

1.53-1.97 (m, 8H),

1.22-1.49 (broad m, 9H),

0.09 (t, 3H, --CH2 --NOS);

starting from trans-3-hexyl-4- [2 - [(tetrahydro-2H-ipyran-2-yl) oxy] -5-hexenyl] -2-oxethanone;

9.N.

trans-3-decyl-4 - [[R) -2-hydroxy-5-hexenyl [-2-oxethanone],

IC spectrum: 3,553, 1,820 cm -1¹, mass spectrum: 292 (ΜH 2 O), starting from trans-3-decyl-4-i (R) -2 - [(tetrahydro-2H-pyran-2-yl) oxy] hexenyl] -2-oxethanone;

9.0.

trans-3-hexyl-4 - [(R) -2-hydroxy-5-tridecenyl] -2-oxethanone,

IR: 3500, 1820, Mass Spectrum: 334 (H2, H2O), from trans-3-hexyl-4 - [(R) -2 - [(tetrahydro-2H-pyran-2-yl) oxy] tridecenyl (-2-oxethanone as starting material;

9.P.

(S) -3-hexyl- (S) -4 - [(R) -2-hydroxy-5-hexenyl] -2-oxethanone, ^XH NMR Spectrum (CDCl3):

5.82 (m, IH),

5.05 (m, 2H).

4.50 (m, IH);

3.85 (m, 1 H),

3.25 (m, IH);

2.20 [m, 2H], from 3-hexyl-4-_l^l(R) -2 - [(tetrahydro-2H-ipyran-2-yl) oxy] hexenyl) -2-oxethanone as a starting material;

9. Q.

trans-3-hexyl-4- [2-hydroxy-tridecyl] -2-oxethanone (mixture of diastereomers), m.p. 44-45 ° C,

3-hexyl-4-; [2- [tetrahydro-2H-pyran-2-yl] oxy] tridecyl] -2-oxethanone as starting material.

Example 10

10. A. Production of the product

565 mg of (S) -1 - ([(2S, 3S) -3-ethyl-4-oxo-2-oxetanyl) N - [(benzyloxy) carbonyl] -L-leucine ethyl octadecyl ester was dissolved in 12 ml of tetrahydrofuran, followed by hydrogenation in the presence of 40 mg of 10% palladium on carbon at room temperature After completion of the reaction, the catalyst is filtered off and the filtrate is evaporated, the residue is taken up in 9 ml of tetrahydrofuran and 71 μΐ of mixed formic anhydride and acetic acid are added dropwise. The reaction mixture was diluted with 5 mL of diethyl ether and washed twice with 2% sodium bicarbonate solution and then washed with water. After drying over sodium sulfate, the mixture was filtered and the filtrate was evaporated. Silica gel chromatography and recrystallization from n-pentane gave N-formyl- (S) -leucine (S) -1j [(2S, 3S) -3-ethyl-4-oxo-2-oxetanyl] methyl ioctadecyl ester, m.p. 61 = C.

10.B. Production of starting material

10. Ba]

The mixture of diastereomers consisting of 85-90% of (R) -2-hydroxy-1,2,2-triphenylethyl (S, Z) -3-hydroxy-11 (R) -2-hydroxy-1,2,2-triphenylethyl ester was obtained as described in 10.Be below. -eicosenoic acids, melting point: 112 to 114 ^QC, from oleylaldehyde and (R) -? - (hydroxydiphenylmethyl) benzyl acetate starting materials;

10.Bb)

By the method described in 10.Bf below, (S, Z) -3-hydroxy-11-eicosenoic acid methyl ester is obtained as a colorless oil.

using (S, Z) -3-hydroxy-11-eicosenoic acid [R) -2-hydroxy-1,2,2-triphenylethyl ester as a starting material;

10.Bc)

The process described in (a) above for the preparation of esters of formula (XV) yields:

(S, Z) -3 - [[tetraliydro-2H-pyran-2-yl) oxy] -1-eicosenoic acid methyl ester containing 10-15% of the (RJ-isomer) using (S, Z) -3 methyl ester -hydroxy-11-eicosenoic acid starting material;

10.Bd)

The process described in 1a) above for the preparation of aldehydes of formula (VIII) affords (S, Z) -3 - [(tetrahydro-2H-pyran-2-yl-Joxy) -11-elkosenal containing from 10 to 15% the corresponding (R) -isomer, using (S, Z) -3 - [(tetrahydro-2H-pyran-2-yl) oxy] -1-eicosenoic acid methyl ester as a starting material;

10.Be)

7.7 g of [R] -α- (hydroxydiphenylmethyl) -benzyl acetate were suspended in 75 ml of tetrahydrofuran under argon and the resulting suspension was cooled to about -75 DEG C. To this suspension was added dropwise a double amount of lithium diisopropylamide solution. The reaction solution is cooled to -113 to -117 ° C and 230 ml of diethyl ether are added during cooling. A solution of (S, ZJ-3 - [(tetrahydro-2H-pyren-2-yl) oxy] -11-eicosene in 20 ml of diethyl ether is then added to the obtained solution, and the reaction mixture is stirred for a further 30 minutes. 20 ml of saturated ammonium chloride solution and the reaction mixture was allowed to warm to room temperature.

The aqueous phase is separated and the organic phase is washed three times with 80 ml of water and washed once with saturated sodium chloride solution. After washing twice with 100 ml of saturated ammonium chloride solution, the solution is dried over sodium sulphate, filtered and evaporated. Recrystallization from methanol several times yields a mixture of distereo32 meres, consisting mainly of (R) -2-hydroxy-1,2,2-triphenylethyl ester (3S, 5S, 13ZJ-3-hydroxy-5 - [(tetrahydro-2H-pyran- 2-yl-Joxy] -13-docosenoic acid, m.p. 91-93 ° C.

10.Bf)

12.75 g of (3S, 5S, 13Z) -3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl Joxy) -13-docosenoic acid (R) -2-hydroxy-1,2,2-triphenylethyl ester The reaction mixture is quenched in 130 ml of methanol and 17.5 ml of 1N methanolic sodium methoxide solution are added to the obtained suspension, when the reaction is complete, poured into 650 ml of saturated ammonium chloride solution and extracted several times with diethyl ether. After drying over sodium sulfate, the mixture is filtered and the filtrate is evaporated, the residue is taken up in 70 ml of n-hexane and the solution is stirred in an ice bath for 1 hour. The white crystals were filtered off and washed with n-hexane. The filtrate was evaporated and chromatographed on silica gel.

A mixture of diastereomers is obtained, which mainly contains (3S, 5S, 13Z) -3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] -13-docosenoic acid methyl ester.

IC spectrum:

'3 473, 1 739, 1076, 1 024 cm'¹.

10.Bg]

The process described in (Da) for the preparation of esters of formula (VI) affords a mixture of diastereomers which contains mainly (2S, 3S, 5S, 13Z) -2-ethyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2) methyl ester. -yl) oxy] -13-docosoic acid, as a colorless oil, using (3S, 5S, 13Z) -3-hydroxy-5 - [[tetrahydro-2H-pyran-2-yl) oxy] methyl ester - 13docosenoic acid and ethyl iodide as starting materials.

10.Bh)

By analogy to Example 3, a mixture of diastereomers is obtained, which mainly contains (2S, 3S, 5S) -2-ethyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl-yloxy) -docosanoic acid methyl ester,

IC spectrum:

738, 1,199, 1,167, 1,132, 1,115, 1,176, 1,023 cm -1¹.

using a mixture of diastereomers, consisting mainly of (2S, 3S, 5S, ZJ-2-ethyl-3-hydroxy-5 - [(tetrahydro-2H-, pyran-2-yl) oxy] -13-docosenoic acid methyl ester;

10.Bi)

0.12 g of a mixture of diastereomers, consisting mainly of (2S, 3S, 5S) -2-ethyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] docosanoic acid methyl ester, The mixture is stirred in 2.5 ml of methanolic potassium hydroxide solution until complete conversion. The cloudy solution was then poured onto 10 ml of water and adjusted to pH 2 with 2N hydrochloric acid. After extraction with diethyl ether, the mixture was dried over sodium sulfate, filtered and the filtrate was evaporated. Chromatography on silica gel yields a mixture of diastereomers, consisting mainly of (2S, 3S, 5S) -2-ethyl-3-hydroxy-5 - [(tetrahyidro-2H-pyran-2-yl Joxy) docosanoic acid, as a colorless oil .

IC spectrum: 1,709 cm⁴.

lO.Bj)

The process described in Aa) for the preparation of ethers of formula IV yields (3S, 4S) -3-ethyl-4 - ((S) -2 - [(tetrahydro-2H-pyran-2-yl) oxy] nonadecyl | - 2-oxetanone as the main constituent of a mixture of diastereomers as a colorless oil,

IC spectrum: 1826 cm^-1using a mixture of diastereomers containing mainly (2S, 3S, 5S) -2-ethyl-3-hydroxy-5 - [(tetrahydro-2H-pyran-2-yl) oxy] docosanoic acid as the starting material.

10.Bk)

In an analogous manner to that described in Example 8:

(3S, 4S) -3-ethyl-4 - [(S) -2-hydroxynonadecyl] -2-oxethanone, m.p. 82-84 ° C (from methanol) from (3S, 4S) -3-ethyl-4 - {(S) -2 - [(tetrahydro-2H-pyran-2-yl) oxy] nonadecyl} -2-oxethanone as starting material.

10.B1)

796 mg of N- [(benzyloxy) carbonyl] -L-leucine was dissolved in 10 ml of methylene chloride, the solution was cooled to 2-3 ° C and 309 mg of dicyclohexylcarbodiimide was added. After 15 minutes the white crystals were filtered off and washed with methylene chloride. The filtrate was evaporated in vacuo at room temperature and the residue was dissolved in 7 mL of Ν, Ν-dimethylformamide. This solution was then added to 574 mg of (3S, 4S) -3-ethyl-4 - [(S) -2-hydroxynonadecyl] -2-oxethanone and 22 mg of 4-dimethylaminopyridine in 6 ml of dimethylformamide. The reaction mixture was stirred for 30 minutes. The solution is then poured onto 100 ml of ice-water and extracted three times with 20 ml of diethyl ether. The combined organic phases were dried over sodium sulfate, filtered and evaporated.

Chromatography on silica gel gave N- [(benzyloxy) carbonyl] -L-leucine (S) -1 - [[(2S, 3S) -3-ethyl-4-oxo-2-oxetanyl] methyl} octadecyl ester as L-leucine as m.p. 44-47 ° C.

Example A

Production of soft gelatin capsules of the following composition:

quantity per capsule oxetanone of formula Г 50 mg carrier base (NEOBEE M-5) 450 μΐ

The active compound of formula I or III is dissolved in NEOBEE M-5 and the solution obtained is then filled into soft gelatin capsules of appropriate size.